

# VIVEKANANAD EDUCATION SOCIETY'S COLLEGE OF PHARMACY

Hashu Advani Memorial Complex, Behind Collectors Colony, Chembur(E), Mumbai-400074

# TABLE OF CONTENTS

Sr. No.	Course	Course Code
1	Modern Pharmaceutical and Medicinal Chemistry	MPH_C_101_T
2	Modern Pharmaceutics	MPH_C_102_T
3	Modern Pharmacology	MPH_C_103_T
4	Modern Analytical Techniques	MPH_C_104_T
5	Study of Natural Products	MPH_C_105_T
	SEMESTER-II	
6	<b>Biostatistics and Research Methodology</b>	MPH_C_201_T
7	Advanced Pharmaceutical and Medicinal Chemistry	MPH_C_202_T
8	Advanced Organic Chemistry	MPH_C_203_T
9 Advanced Pharmaceutics - I		MPH_C_204_T
10	Advanced Pharmaceutics - II	MPH_C_205_T
11	Quality Assurance Systems	MPH_C_212_T
12	Pharmaceutical Quality Management	MPH_C_213_T
13	Drug Metabolism	MPH_C_217_T
14	<b>Experimental Techniques in Pharmaceutical Sciences</b>	MPH_C_299_L
15	Rational Drug Design	MPH_E_221_T
16	Advanced Biochemistry	MPH_E_222_T
17	Green Chemistry	MPH_E_223_T
18	Drug Regulatory Affairs	MPH_E_224_T
19	Cosmeticology	MPH_E_225_T
20	Polymers in Pharmacy	MPH_E_226_T
21	Drug Evaluation Techniques	MPH_E_227_T
	SEMESTER- III and IV	
22	Descende Work	MPH_C_301_D
22	Kesearch Work	MPH_C_401_D



Course: Modern Pharmaceutical and Medicinal Chemistry (CBCS)						
Course Code: MPH_C_101_T		First	Year M. Pharm	Semester: I		
Type of course: Theory		Contact Hours	: 4 Hours/week (4L + 1T)	<b>Total Contact Hours:</b> 60		
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Semester assessme	-end ent	
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End seme Examina	ester tion	
Max.	Marks:	15	5	80		
Pre-requisites:		Before undertakinfollowing:1.Basics of p2.Basics of p	g the course, students should proteins specifically receptors a ADME properties and drug del	have knowled and enzymes ivery systems	ge of the	
Cours	e Objectives:	<ul> <li>After completion of course students will be able to know:</li> <li>Different stages of drug discovery</li> <li>Role of medicinal chemistry in drug research</li> <li>Different techniques for drug discovery</li> <li>Various strategies to design and develop new drug like molecules for biological targets</li> </ul>				
Cou	rse Outcomes	Upon completion of be able to:	of the course the student shall	PO Mapped	PSO mappe d	
CO1	Recall the con types, SAR, r enzyme kinet	ncept of protein fold nechanism of action ics and principles of	ing, receptors and their of certain class of drugs, enzyme inhibitors	1, 2, 3, 7, 8, 11	1, 2, 3	
CO2	Explain and illustrate the principles and applications of medicinal chemistry to impart knowledge about recent advances in the field of medicinal chemistry at the molecular level including different techniques for the rational drug design.1, 2, 3, 4, 6, 7, 111, 2, 3					
CO3	Application of the gained knowledge in basic research of 1, 2, 4, 6, 7, 1, 2, 3 rational design of enzyme inhibitors along with their 8, 11 metabolic profile and stereochemistry.					
CO4	O4Evaluating and interpreting the role of chirality in selective and specific therapeutic agents to realize that stereo-selectivity1, 2, 3, 4, 5, 10, 111, 2, 10, 11					
	Topics covered:					

Unit I:	Drug Discovery	Hours: 5				
Historical perspective						
• Le	ad Discovery					
• Le	ad Modification – identification of the pharmacophore, functional group	p modification,				
privileged	structures and drug-like molecules, modifications to increase potency and	nd the				
	ndex, modifications to increase oral bioavailability	11				
	Receptors	Hours: 10				
• Ba	isic ligand concepts – agonist, antagonist, partial agonist, inverse ago	onist, efficiency				
	y torractions (Forces) involved in drug recentor complexes					
• III	ecentor theories – occupancy theory, rate theory and activation theory					
• Re	eceptor classification – the four superfamilies					
• Re	cceptor binding assays- measurement of Kd, Bmax and IC50					
• To	pographical and stereochemical considerations in drug -receptor interac	ctions				
Unit III:	Prodrugs and Drug Delivery Systems	Hours: 13				
• Er	zyme activation of drugs, utility of prodrugs – aqueous solubility,	absorption and				
distribution	n, site specificity, instability, toxicity, poor patient acceptability, formula	ation problems.				
• Ca	rrier-linked prodrugs - carrier linkages for various functional group	s, carrier-linked				
bipartite p	rodrugs, macromolecular drug carrier systems, tripartite prodrugs, m	utual prodrugs,				
bioprecurs	or prodrugs (hydrolytic activation, elimination activation, oxida	tive activation,				
reductive	activation, nucleotide activation, phosphorylation activation, sulfation	activation and				
decarboxy	lation activation).	<b>6</b> 1 ·				
• Se	It study of specific examples of drugs that have been converted to prod	rugs for solving				
problems r	elated to ADME and their release mechanisms.	ativation at the				
• Se	in study of produces involving specific dissue targeting of specific a	cuvation at the				
Unit IV:	Drug Metabolism	Hours: 18				
• In	troduction to xenobiotic/drug metabolism and its relation to other d	lefence systems				
(Physical l	parriers, excretion, immune system).	erence systems				
• Ty	ppes of reactions (I and II), consequences of drug metabolism (DM	(1) [inactivation,				
bioactivati	on, prodrugs], organs of DM, localization of drug metabolizing en	nzymes, factors				
affecting d	rug metabolism.					
• Cy	tochrome P450s: Introduction to the family of enzymes, their cla	assification and				
nomenclat	ure.					
• C	YP450 catalytic cycle, different types of reactions catalyzed by CY	(P450s and the				
	18 of catalysis.	nical substratas				
• Il	and CTF450s involved in Divi, then distribution and properties, typothese substrates specific inhibitors induction of CVPs and specific induc	pical substitutes,				
Discussion of glucuronosyltransferases sulfotransferases glutathione S-transferases N-						
acetyl transferases, and FMO [on lines similar to that specified for CYPs as listed above].						
• Self study of alcohol/aldehyde dehydrogenases, xanthine and aldehyde oxidase, epoxide						
hydrolase,	esterases, azo and nitro reductases (reactions catalyzed be these enzym	les, mechanisms				
of the reac	tions, typical substrates/inhibitors/inducers)					
Unit V:	Enzymes	Hours: 14				
• In	roduction to enzymes, binding site, specificity of enzyme catalyzed re	actions and rate				
acceleratio	n, Michaelis Menten kinetics and methods for plotting enzyme kinetic c	lata.				
• <u>M</u>	echanisms of enzyme catalysis – covalent catalysis, acid-base catalys	sis, electrostatic				
$\bullet$ Contraction C	come examples of the mechanisms of enzyme catalysis	decarboxylases				

aminotranst	sferases), nicotinamide and flavin (two-electron mechanism, one-electron mechanism							
and hydride	e transfers), folic acid and thiamine (one carbon transfer reactions).							
• Sel	elf study of Hanes plot, Cornish-Eisenthal Bowden plot.							
• Sel	f study of roles of coenzymes – biotin, coenzyme A, cyanocobalamin, vitamin K.							
	Books:							
	1. The Organic Chemistry of Drug Design and Drug Action, Silverman R. B.,							
	Academic Press.							
	2. Textbook of Drug Design and Discovery, Eds. Krogsgaard-Larsen P.,							
	Liljefors T., Madsen U., Taylor & Francis.							
	3. Lehninger – Principles of Biochemistry, 4th edition.							
	4. Medicinal Chemistry: An Introduction, Thomas G, Wiley.							
	5. Drug Discovery – A History, Sneader W, John Wiley & Sons, Ltd.							
De	6. Comprehensive Medicinal Chemistry, Series Ed., Hansch C., Pergamon							
Referenc	Press.							
e	7. Wilson and Gisvold's, Textbook of Organic Medicinal and Pharmaceutical							
material:	Chemistry, Lippincott-Raven							
	8. Foye's Principles of Medicinal Chemistry, Lippincott Williams and Wilkins.							
	9. Drug Metabolizing Enzymes-Cytochrome P450 and Other Drug							
	Metabolizing Enzymes in Drug Discovery and Development, Lee JS, Obach SR and							
	Fisher MB, Marcel Dekker, Fontis India, 2003							
	10. Pharmaceutical Profiling in Drug Discovery for Lead Selection, Borchardt							
	RT, Kerns EH, Lipinski CA, Thakker DR and Wang B, AAPS Press, 2004							
	11. Drug Metabolism – Current Concepts, Ionescu C and Caira MR, Springer							
	International Edition							
	12. Handbook of Drug Metabolism, Woolf TF, Marcel Dekker, 1999.							

Course: Modern Pharmaceutics (CBCS, 2016-17)								
Cou MPH	<b>rse Code:</b> [_C_102_T	First Year M. Pharm			Seme	ster: I		
Type of course: Theory		Contact H	Iours: 4 Hours/wee	k (3L + 1LT)	Total	Total Contact Hours: 60		
Course assessment Methods:		Cont	tinuous mode of ass	essment	Ser	Semester-end assessment		
Assessment Tool*:		Theory Sessional Exam	Attendance	Total Internal Assessment	End	End semester Examinatio		
Max.	Marks:	15	5	20		80		
Pre-re	equisites:	Basic knowledge	about pre-formulation	n, validation, GM	P and scale-u	p techniques.		
Cours Objec	e tives:	<ol> <li>The elements of pre-formulation studies.</li> <li>Various aspects of excipients and introduction to polymers</li> <li>Optimization techniques &amp; Micromeritics</li> <li>Stability Testing, sterilization process &amp; packaging of dosage forms</li> </ol>						
Cours	e Outcomes:	The learner should be able to:			PO M	apped	PSO Mapped	
CO1	Understand compressio	the concepts of pan, optimization.	re-formulation, micro	omeritics, tablet	1, 3, 4, 6, 7		1, 2, 3	
CO2	Apply the design of sa	preformulation an afe, efficacious, stab	d excipient knowle ble and quality formu	dge for proper lations.	1, 2, 3, 4, 6	1, 2, 3, 4, 6, 7, 8, 10, 11 1, 2, 3		
CO3	Investigate	various aspects of s	colubility, dissolution	and stability	1, 2, 3, 4, 6	1, 2, 3		
CO4 Analyze th and devise		e formulation parameters, apply optimization techniques suitable formulation composition.			1, 2, 3, 4, 5, 10, 11	1, 2, 3, 4, 5, 6, 7, 8, 9,       1, 2, 3         10, 11       1		
Topics covered:								
Unit I	Drug Stabi	rug Stability				Hours: 9		
•	<ul> <li>Importance and need for stability testing</li> <li>Revision of degradation pathways, kinetics, physical stability</li> <li>Solution and Solid state stability, pH stability profiles, v and u graphs, package evaluation, ICH guidelines, statistical aspects in derivation of shelf life.</li> <li>Self study- Calculations for shelf life based on degradation kinetics</li> </ul>							

Unit II	Solubilization and Dissolution	Hours: 14				
·	<ul> <li>Importance of aqueous solubility of drugs, particularly NCEs, surfactant systems and phase diagrams, polymeric surfactants, cosolvents, complexation, solid state manipulations, cyclodextrins, drug derivatization, salt screening.</li> <li>Revision of equations of dissolution and factors affecting dissolution, intrinsic solubility and dissolution rate, validation of testing, different equipments (emphasis on USP apparatus 4), Dissolution of TDDS, particulates, gels &amp; ointments, comparison of profiles by f2 analysis, development of dissolution method, relevance of dissolution testing in ANDAs, bio-relevent media, BCS classification, IVIVC- study design and interpretation</li> <li>Self study- Calculations based on various solubility parameters and equations of dissolution. Pharmacopoeial dissolution apparatus, data treatment of dissolution profiles.</li> </ul>					
III	Excipients and introduction to polymers	Hours: 7				
•	<ul> <li>Role of excipients, purity, safety and toxicity with reference to routes of exposureoral, inhalational, parenteral, others; regulatory aspects, risk assessments, Harmonization of excipient standards like residual solvents class 1,2,3.</li> <li>Different classes of excipients - surfactants, special lipids, superdisintegrants, gelling agents, colours and flavours, sweetening agents, co-processed excipients.</li> <li>Definition of polymers, classification; concept of properties used in characterisation, methods of polymerisation, biocompatibility evaluation, applications.</li> </ul>					
Unit III:	Optimisation Techniques	Hours: 8				
•	Definition, Need, Advantages, description of terms such as independent varial response surface, contour plots, polynomial equations. Simplex and factorial designs in optimisation Application of optimisation techniques in QbD in product development Self study: Placket-Burman design, central composite designs	ble, response parameters,				
Unit IV:	Preformulation	Hours: 12				
•	<ul> <li>Scope of Preformulation-Role &amp; importance in New Drug Discovery &amp; Approval process-Lead optimization, Steps in Designing the preformulation evaluation of a new drug, critical issues and problems/constraints</li> <li>Key Areas in Preformulation research- Bulk Characterization, Solubility Analysis, Stability Analysis, Compatibility with common excipients</li> <li>Preformulation aspects for Tablets, Injectables, Liquid preparations, Protein &amp; peptide drugs.</li> <li>Self study: case study of drug exhibiting various polymorphic forms, drug excipient compatibility</li> </ul>					
Unit V:	nit Powder Technology (Micromeritics) Hours: 10					
Revisi	<ul> <li>vision of following topics:</li> <li>Important definitions &amp; Units</li> <li>Importance of particle size in pharmaceutical development.</li> <li>Fundamental &amp; derived properties of powders</li> <li>Particle size reduction –comminution mechanisms &amp; equipment</li> <li>Methods of particle size determination (emphasis on basic principles &amp; interpretation of data)</li> </ul>					

-	Theory of comminution, milling rate (various mathematical relationships), concept of milling/grinding				
	index, energy for comminution, distribution and limit of comminution				
	Compaction of powders				
•	Definitions of compression & consolidation, deformation mechanisms of matter, s	teps in compaction of			
	tablets (in detail),				
•	Theoretical aspects- Force Volume relationships/porosity –pressure equations				
	(Heckel's Law & equation), Granulation of powders –theory,				
-	Effect of compaction pressure on various tablet properties, Energy for compaction	& effect			
	of lubrication of granules, instrumentation of tablet presses ( principles)				
•	Self study: case studies on compaction behaviour of two excipients				
	Books				
	1. Drug Stability Principles and Practices by Carstensen J, Marcel Dekker, 3rdedn, Vol 107, 1990.				
	2. Pharmaceutical Stress testing by Baertschi SW, Taylor and Francis, Vol 153, 2005.				
	3. Pharmaceutical characterisation of Pharmaceutical Solids by Brittain HG, Marcel Dekker, Vol 70, 1995				
	4. Preformulation in Solid Dosage Form Development by Adeyeye MC, Brittain HG, Informa Healthcare,				
	Vol 178, 2008.				
Refer	5. Dissolution, Bioavailability and Bioequivalence by Abdou HM, Ed A. Gen	naro, B. Migdalof, Mack			
ence	Printing Company,1st edn, 1989.				
mate	6. Pharmaceutical Bioequivalence by Welling PG, Francis LST, Dighe SV, Marcel Dekker, Inc., Vol. 48,				
rial:					
1 1011	7. Pharmaceutical Dissolution Testing by Banaker U, Marcel Dekker, Vol 49, 199	92. Dellas a 1000			
	8. Excipient toxicity and safety by weiner M L, Kotkoski LA, vol 103, Marcel L	Jekker, 1999.			
	9. Martin's Physical Pharmacy and Pharmaceutical Sciences, by Sinko PJ, Ed	Lea & Feiger, Lippincott			
	Williams & Wilkins, othean, 2010.	Deller Aller de Wel 121			
	10. Modern Pharmaceutics by Banker GS, Ed Banker GS & Rhodes C1, Marcel	Dekker, 4th edn, Vol 121,			
	2003. 11 Pharmaceutical Statistics by Bolton S. Marcel Deckker, 3rdedn. Vol.80, 1007				
	11. I narmacculcal Statistics by Dolton S, Marcel Deckker, Studuli, VOI 60, 1777	•			

Course: Modern Pharmacology (CBCS Revised 2019)							
Course Code:		First Year M. Pharm		Semester: I			
Туре с	of course:						
Theor	y	Contact Hours: 4 Hou	irs/week $(3L + 1)$	<b>I</b> )	Total	Con	tact Hours:
Course Metho	e assessment ds:	Continuous mode of a	assessment	S	emeste	er-enc	l assessment
Assess	ment Tool*:	Theory Sessional Exam	Attendance	E	End semester Examination		
Max. N	Marks:	15	5			80	0
Pre-requisites:		Learner should be aware of Pathophysiology and conventional pharmacotherapy of CNS, CVS, and Diabetes Mellitus. Learner should know basic concepts of pharmacokinetics, pharmacodynamics and immunology. Learner should be aware of pharmacology of antimicrobial agents.					
Course Objectives:		The course aims to impart knowledge about advances in following therapeutic areas: CNS, CVS and Diabetes Mellitus. The course aims to impart knowledge of pharmacokinetics and pharmacodynamics. Also covers the mechanism of dependence and tolerance, Apoptosis, immunopharmacotherapy.					
	Course O	utcomes: Upon completion	of the current	PO	C	PSO mapped	
	<b>Course</b>	the learner would be able to	nd concents of		ped	0.4	2 DSO1 DSO2
CO1	Pharmacokine	tics, pharmacodynamics.	nd concepts of	1, 5, 0	, 0, 9	PSO3, PC 3	
CO2	Explain the factor mechanisms of and apoptosis.	ctors affecting drug responsiv f drug dependence and micro	eness, bial resistance	1,3,4, 8,	6, 7, 9	QA	A 3, PSO1, PSO2, PSO3, PC 3
CO3	Explain Immu	nopharmacology and advance apy of CNS, CVS and Diabete	es in the es Mellitus.	1,3,4, 9	6, 8,	QA	A 3, PSO1, PSO2, PSO3, PC 3
phumucouler		Topics	covered:	_			······
Unit I:	Pharmac	okinetics					11
Drug	Absorption, dist	tribution, metabolism and exc	eretion.				
• Mechanisms of transport of drug across membranes.							
Trans	porters involved	l in drug absorption, distribut	ion and excretion	process	ses.		
• Sel	f study-Drug ef	flux pathways and experimen	tal methods to stu	ıdy drug	g transp	oort.	
Pharn	nacokinetic facto	ors affecting drug action					
Unit I	[: Mechan	ism of drug action					11

- Classification of receptors and description of each class with examples.
- Signal transduction mechanisms.
- Detailed description of signal mediation through cascades after adrenergic, muscarinic, GABAergic, insulin receptor stimulation.
- Regulation of receptors, their involvement in various biological processes including diseases resulting from receptor malfunction and their role in pharmacotherapeutics.
- Regulation of intracellular calcium.
- Pharmacodynamic interactions in a multicellular context e.g. Vascular wall (interactions of physiological ligands and drugs in pathophysiological setting).
- Self study- Classification and characterization of receptors-IUPHAR (Eg. 5-HT receptors)

Unit III:	Functions of sodium and potassium channels and therapeutic potential of channel modulators.	Hours: 3
Unit IV:	Factors affecting drug responsiveness.	Hours: 3

- Alteration in concentration of drug that reaches receptors.
- Variation in concentration of an endogenous receptor ligand.
- Alteration in number and function of receptors.
- Clinical selectivity: Beneficial vs. toxic effects of drugs.
  - a. Beneficial and toxic effects mediated by the same receptor effector mechanism.
  - b. Beneficial and toxic effects mediated by identical receptors but in different tissues or by different effector pathways.
  - c. Beneficial and toxic effects mediated by different types of receptors.
- Desensitization, tachyphylaxis.
- Drug tolerance.

0							
Unit V:	Cellular and molecular mechanisms of	Hours: 4					
• Drug de	• Drug dependence (Eg. Morphine).						
Microb	al resistance.						
Unit VI:	Advances in therapy of	Hours: 18					
• CNS: D	epression, Alzheimer's disease, Psychosis, Parkinson's disease, Epilepsy.						
• CVS: H	ypertension, Angina Pectoris, Congestive cardiac failure, Arrhythmia.						
Manage	ement of Diabetes Mellitus.						
Unit VII:     Apoptosis     Hours: 4							
Molecu	lar biology, physiological, pharmacological implications and therapeutic pro	spects.					
• Self stu	dy – Interaction between cell, growth factors and extracellular matrix.						
Unit VIII:	Immunopharmacology	Hours: 6					
• Introdu	ction to immunopharmacology, immunomodulators, Immunostimulants and						
Immune	osuppressants.						
• Self stu	dy-Autoimmunity						
	Books						
Reference	1. Rang and Dale's pharmacology Elsevier Churchill Livingston.						
material:	2. Lange's Basic and clinical pharmacology, Katzung B.G. Masters S.B.	, Trevor					
A.G. Tata McGraw Hill.							

3.	Goodmann and Gilman's pharmacological basis of therapeutics, Edited by
	Laurence Brunton, Bruce Chabner and Bjorn Knollman, McGraw Hill.
4.	Pharmacological reviews, Annual reviews Inc.
5.	Advances in pharmacology, Academic Press.
6.	Trends in Pharmacological Sciences, Cell Press Elsevier Publication.

Course: Modern Analytical Techniques (CBCS)						
Cou MPH	urse Code: H_C_104_T	First Year M. Pharm		Semester: I		
Type o Theor	of course: Y	Contact Hours	: 4 Hours/week (3L + 1T)	Total Contact 60	Hours:	
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Semester	-end ent	
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End semester Examination		
Max. 1	Marks:	15	5	80		
Pre-re Cours	equisites: ee Objectives:	<ul> <li>Before undertakin following:</li> <ol> <li>Liquid-liq mass trans</li> <li>Adsorption between p</li> <li>Carbocation</li> <li>Difference</li> </ol> <li>After completion of Chemicals</li> <li>The analys</li> </ul>	ig the course, students should uid extraction- Partition coeffi- fer n, adsorption isotherms, qua rotons, neutrons and electrons on stability, fission and rearran e between protons, neutrons and of course students will be able t and Excipients sis of various drugs in single ar	d have knowled cient, molecular antum theory, o gements. d electrons to know:	ge of the diffusion, difference	
G		<ul> <li>forms</li> <li>Theoretical and practical skills of the instruments</li> </ul>				
Cou	irse Outcomes	be able to: <b>PO Mapped</b>			PSO mappe d	
CO1	Recall with expectroscopy, electrophores	xamples the termino , chromatography, X is, potentiometry an	1, 2, 3, 8, 11	1, 2, 3		
CO2	Explain and i applications of chromatograp potentiometry	llustrate the theory, of various techniques ohy, X-ray diffractio y and thermal analys	1, 2, 3, 4, 6, 8, 11	1, 2, 3		

CO3	Apply the knowledge gained to calculate concentration by	2, 3, 4, 1	1	1, 2, 3	
	UV-visible spectroscopy, predict the IR frequencies, number				
	of signals in NMR and fragmentation pattern in MS for simple				
	organic compounds				
<u>CO4</u>	Duradiat the anastroscopic helession of malaculas	2240	11	1 2 2	
04	Predict the spectroscopic behavior of molecules	2, 3, 4, 8	, 11	1, 2, 3	
	Topics covered:				
Unit 1	: Multicomponent analysis of drugs using UV- Vis. spectrosco	ру: б	Hou	rs: 6	
•	Simultaneous equation method, Absorbance ratio method, Diffe	rence spec	ctrosco	py,	
	Derivative spectroscopy and Introduction to Ratio derivative spe	ectroscopy	',		
•	Self-study-Pharmaceutical applications of above techniques (1.1	)			
Unit 2	: F.T.I.R spectroscopy:		Hou	rs: 6	
•	Construction and working, newer sampling techniques.				
•	Interpretation of I.R. spectra in mid I.R. region (aliphatic and ar	omatic coi	npoun	ds for	
	simple compounds such as amines, alcohols, amides, nitriles, ke	tones, ald	ehydes	, esters,	
	acids, nitro and anhydrides).				
•	Self-study-Interpretation of recorded I.R spectra of drugs and or	ganic com	pound	s.	
Unit 3: NMR spectroscopy: Hours: 10				rs: 10	
•	1H- NMR: Basic theoretical concepts-(Self-study-chemical shif	t, splitting	patter	n and	
	coupling constant-2 hrs), non-first order spectra, methods to ma	ke comple	x spec	tra	
	simple, FT-NMR.				
•	13C-NMR: Theory and Principle.				
•	Applications of 2D-NMR (only COSY and HETCOR)				
Unit 4	: Mass Spectrometry:		Hou	rs: 10	
•	Different ionization techniques-EI, CI, FD, FI, MALDI, API (A	PPI, APC	I, ESI)		
•	Different analysers-Quadrupole, TOF, QTOF, Ion cyclotron, Ion	n trap.	_		
•	Concepts for interpretation of mass spectra-Molecular ion peak,	base peak	, Isoto	pe	
	abundance, fragmentation pathways- $\alpha$ fission, $\beta$ fission, MacLa	farty rear	rangen	nent,	
	Retro Diels Alder rearrangement, Tandem mass (MS-MS).		TT	2	
Unit 5	: Terminologies of chromatography:		Hou	rs: 3	
Self-st	udy-Incoretical plate, HEIP, Plate theory, Rate theory, Van Deel	nter equat	10n, 18	ocratic	
factor.	, Gradient entron, capacity factor, selectivity factor, Resolution,	taning rac	lor, asy	minetry	
Unit 6	: Advances in chromatography:		Hou	rs: 11	
•	HPLC-Ion pair chromatography, Chiral chromatography (Chiral	stationary	y phase	es, use of	
	mobile phase additives, precolumn derivatization, chiral detecto	rs), UPLC	, Self-	Study-	
	Advances in HPLC detectors (1 hr)				
•	Supercritical Fluid Chromatography-Principle, Instrumentation	and pharm	aceuti	cal	
	applications.				
•	Self-study-HPTLC-Principles, Instrumentation and applications	including	finger	print	

ana	alvsis.		
• Ga	s chromatography-Headspace analysis.		
• Ge	l electrophoresis-Principle. Instrumentation and applications		
Unit 7: Hy	nhenated techniques:	Hours: 4	
• Int	erfaces used in and applications-MS. LC-MS. LC-MS-MS		
• Int	roduction to LC-NMR and MALDI-TLC.		
Unit 8: Th	ermoanalytical techniques:	Hours: 5	
• Pri	nciple, instrumentation and applications including interpretation of data	a in pharmacy	
for	: Self-study-DSC and TGA		
• TN	IA (Thermo mechanical analysis)		
• Int	erpretation of DSC and TG curves of suitable compounds/drugs (Self-s	tudy)	
Unit 9: M pharmace	<b>Example 2</b> (icroscopy: Principle, Instrumentation, sample preparation and utical applications of	Hours: 5	
Scanning E	Electron Microscopy, Transmission Electron Microscopy, Atomic Force	e Microscopy,	
Confocal m	nicroscopy.		
	Books:		
	1. Chromatographic methods by A.Braithwaite & S.J.Smith, Kluwe	er Academic	
	publishers, Netherlands, London, USA.		
	2. Thermal Analysis of Pharmaceuticals by Craig, Informa, CRC Pr Reprint.	ress, Indian	
	3. Practical Pharmaceutical Chemistry by A.H.Beckett and J.B.Ster	lake. fourth	
	edition, part two, CBS Publishers and Distributors.	,	
	4. Spectrometric Identification of Organic compounds by R.M.Silv	erstein,	
	F.X.Webster, D.J.Kiemle, Latest edition, John Wiley & Sons		
	5. Applications of absorption spectroscopy of organic compounds b	y John Robert	
Referenc	6 Organic Spectroscopy by William Kamp DALCDAVE		
e	7 Textbook of Pharmaceutical Analysis by K A Connors Wiley I	nterscience	
material:	Publications.		
	8. Introduction to Spectroscopy by D.L.Pavia, G.M.Lampman & G	.S.Kriz.	
	9. Remington: The Science & Practice of Pharmacy, 20th edition, V	ol. 1, Lippincot	
	Williams & Wilkins		
	10. Introduction to Modern Liquid Chromatography by L.R.Snyder, edition	J.J.Kirkland 3 <sup>rd</sup>	
	11 Chiral separations by Liquid Chromatography and Related Tech	nologies	
	Chromatographic Science Series by Hassan Y Imran Ali Vol	0.	
	12. Static head space gas chromatography Theory & practice by Bru	no Kolb &	
	L.S.Ettre.	no more a	
	13. Encyclopedia of Chromatography, by Jack Cazes, 3rd edition, Ve	ol.1,2 & 3.	
	14. Online LC-NMR and Related techniques by Klasu Albert, John	Wiley & Sons	
	15. LC-MS- A Practical Users guide, by Marvin C. McMaster.		

Course: Study of Natural Products (CBCS)						
Course Code: MPH_C_105_T		First Year M. Pharm		Semester: I		
Type of course: Theory		Contact Hours:	4 Hours/week (3L + 1T)	Total Contact Hours: (		Hours: 60
Course assessment Methods:		Continuous mode of assessment Sem		emester-end assessment		
Assessment Tool*:		Theory Sessional Exam	Attendance	End semester Examination		ester tion
Max.	Marks:	15	5		80	
Pre-requisites:		Basic knowledge of	of biological sources of various	medicinal	l plants	8
Course Objectives:         After completion of the course students will be able to understand extraction of phytochemcials and understand the significance of herbal drugs in drug discovery and development			erbal			
Course Outcomes: Upon completion of the course the student shall be able to:       PSO mapped         PO Mapped       Mapped         d       d				PSO mappe d		
CO1	Define and su in drug disco related applic	summarize phytochemicals and herbal drugs used 1, 2, 3, 8, 11 eovery, nutraceuticals, immunoglobulins and ications		, 11	1, 2, 3	
CO2	Explain the u as immunogle	se of herbal drugs as obulins and related a	excipients, in utraceuticals, pplications	s, 1, 2, 3, 4, 6, 1, 2, 3 8, 11		1, 2, 3
CO3	Apply the kr herbal drugs	he knowledge gained to isolate phytochemicals from 2, 3, 4, 11 rugs and carry out standardization		1	1, 2, 3	
CO4	Summarize th Pharmacopoe	ne information of van bia	rious herbs from Herbal	2, 3, 4, 8, 11 1, 2, 3		
		]	Fopics covered:			
Unit 1	: Introduction	to study and resea	rch in herbal drugs:		Hou	rs: 4
• Different approaches to plant selection, collection and processing for 2 herbal drug research (Random selection, use of ethnobotanical information, Use of chemotaxonomical classification etc.).						

• Rec	• Recent advances in concept of authentication & standardization - significance of					
che	chemotaxonomy and DNA finger-printing with respect to gene expression for secondary					
me	metabolites.					
Unit 2: Ext	traction of phytochemicals	Hours: 18				
• Co	ncepts of extraction with respect to activity guided fractionation & isola	ation of				
Ma	rkers/Biomarkers.					
• Rec	• Recent trends in extraction, optimization of extraction, and analysis of the					
phy	tochemicals of different classes.	1 . 1 . (2)				
• Det	tail discussion of large-scale extraction of the following: (1) Optum alk $(2)$ S $(2)$ S $(3)$ $(4)$ C $(5)$ $(5)$ $(5)$ $(7)$	aloids (2)				
Pip	erine (3) Sennosides (4) Carreine (5) Cinchona alkaloids (6) Rutin (7)	Lemon grass oil				
(8) Sal	Fatchoun on (9) Steroids (Diosgenin from an sources)	ringinlag for all				
• Sei	r-study- preparation of now chart and discussion of physicochemical p.	finciples for all				
141 2						
Unit 3: Na	tural products in drug discovery and drug development	Hours: 8				
• Ro	e of natural products as leads to the design of new drugs with case hist	ory with				
exa	mples e.g., artemisinin, taxane, camptothecin and a few others.					
• Nat	tural products derived combinatorial libraries and their significance in o	lrugs discovery				
pro	gramme (HITS and leads).					
• Sel	f-study- Discussion of lead molecules in drug discovery					
Unit 4: Stu to sources,	dy of following excipients of natural origin in NDDS with respect preparation, composition and application	Hours: 16				
• Nat	tural dyes & colorants, sweeteners, flavours and fragrant materials					
• Kaj	ppa carrageenans, galactomannans, glucomannans, cellulose derivative	s, lecithin, &				
alg	inates.					
• Sel	f-study- Role of excipients mentioned above, in formulations, with exa	mples				
Unit 5: A <sub>l</sub> and therap	oplication of immunoglobulins from plant sources in diagnosis	Hours: 4				
Unit 6: Nu	traceuticals and their role in health care.	Hours: 4				
Study of fo	llowing classes of herbs with two or three suitable examples of each: (1	) Antioxidants				
(2) Immuno	omodulators (3) Antihyperglycemics (4) Hepatoprotectives					
Unit 7: Sta	tus of natural products in official books	Hours: 6				
• Inti	oduction to Herbal Pharmacopoeias of different countries					
• Mo	nographs of natural products in other official books					
• Sel	f-study-Discussion of monograph of few substances of natural origin					
	Books:					
	1. Pharmacognosy Phytochemistry – Medicinal Plants- Jean Brunet	ton. Lavoisier				
Referenc	Publishing, Paris.	, 2				
е	2. Text book of Pharmacognosy- Trease and Evans- 14th edition. E	lsevier science				
material:	3. Transgenic Plants- R. Ranjan- Agro Botanica, New Delhi.					
	4. Transgenic Plants-A Production system for Industrial and Pharma	aceutical				
	Proteins. By Meran Owen, Jan Pen- John Wiley.					
	5. Medicinal Plant-Their Bioactivity, Screening and Evaluation- CS	IR.				

6. Homeopathic Pharmacopoeia of India- Publisher Ministry of Health.
7. The Ayurvedic Formulary of Part I & II- Publisher Ministry of Health.
8. Chinese Materia Medica-You-Ping Zhu- Harwood Academic Publishers.
9. India Materia Medica- Nadkarni A.K. –Bombay Popular Prakashan.
10. Phytochemical Methods - J.B.Harbone - Chapman and hall
11. Cultivations and Processing of Medicinal Plants-Ed. by L. Hornok-John Wiley.
12. Introduction to Flavanoids-Bohrn Bruce A. – Herwood Academic Publishers.
13. Cultivation and Utilization of Aromatic plants – Ed. By Atal C. K. and Kapur
B.MCSIR.
14. Plant Tissue and Cell Culture Ed. H.E. Street – Blackwell Scientific
publications.
15. Aflatoxin- Leo A. Goldblatt- Academic Press New York.
16. Microbial Toxins- Ciejler, Kadis and Ajl- Academic press.
17. Antimicrobial in Food – Alfred larry Branen, P. Michael Davidson Publishing
house
18. Chemical plant Taxonomy T. Swain, 1963. Academic Press, London.
19. Plant Taxonomy and Biosystematics .C.A Stace, 1985. Edward Arnold, London.
20. Modern methods of plant analysis K. Paech, 1956., Springer-Verlag.
21. Indian Herbal Pharmacopoeia, Vol. 1&2, RRL, IDMA, 1998, 2000.
22. Indian Pharmacopoeia, 2010.
23. Standardization of Botanicals, V. Rajpal, 2002. Eastern Publishers, New Delhi.
24. Natural Compounds as Drugs – Vols. I & II, Editor- Frank Petersen, René
Amstutz, Die Deutsche Bibliothek, Germany.
25. Quality control of Herbal Drugs: An Approach to evaluation of Botanicals,
Pulok Mukherjee - Riddhi International
26. Chemicals from Plants: Perspectives on Plant Secondary Product, Walton &
Braun, Imperial College Press.
27. Towards Natural Medicine Research in the 21st Century H. Ageta, N. Aimi et al
Excerpta Medica, International Congress Series 1157.



Course: Biostatistics & Research Methodology (CBCS)					
Cou MPH	ırse Code: H_C_201_T	First Year M. Pharm		Semester: II	
Type of Theor	of course: y	Contact Hours: 4 Hours/week (3L + 1T)		Total Contact Hours: 6	
Cours Metho	e assessment ods:	Continuous mode of assessment		Semester-end assessment	
Assess	sment Tool*:	Theory Sessional Attendance Exam		End semester Examination	
Max. 1	Marks:	15	5	5 80	
Pre-re	equisites:	<ul> <li>Students must be aware about the following:</li> <li>Importance of research</li> <li>Basic terminologies like hypothesis, aim, objectives, rationale ir research</li> </ul>			
<ul> <li>This Course aims to:         <ul> <li>To train students in general research methodologies like of study design, review of literature, randomization, types of</li> <li>To train students in Biostatistics to enable them to statistic evaluate their research data</li> <li>To train students in the basic concepts of medical research including informed consent, , concepts like autonomy, be and non-maleficence, as well as about the declaration of I and other guidelines like ICH GCP, Nuremberg code while thical conduct of clinical trials.</li> <li>To train students on the CPCSEA guidelines for animal h and animal house facilities including the transport, storag care of animals. As well as about the basic procedures to followed to ensure the efficient management of animal house facility at the site</li> </ul> </li> </ul>			bjectives, f studies cally h neficence Helsinki ch govern andling e and be buse		
Course Outcomes		Upon completion of the course the student shall			PSO
PO Mapped			mappe d		
CO1	Students will like objective randomization	dents will be able to explain basic research methodologies e objectives study design, review of literature, domization, types of studies			1,2,3
CO2	Students will	be able to explain, a	nalyze the data and apply the	1,2,3,6,7,8,9,	1,2,3

	statistical principles in the evaluation of the research data	10,11			
CO3	Students will be able to explain the basic concepts of medical research including informed consent, , concepts like autonomy, beneficence and non-maleficence, as well as about the declaration of Helsinki and other guidelines like ICH GCP, Nuremberg code which govern ethical conduct of clinical trials	1,2,3,6,7 10,11	,8,9,	1,2,3	
CO4	Students will be able to explain the basic facilities in animal handling and animal house facilities like transport, storage and care of animals. As well as about the basic procedures to be followed to ensure the efficient management of animal house facility at the site.	1,2,3,6,7,8,9, 10,11		1,2,3	
	Topics covered:				
Biosta	tistics				
Diosta					
Unit 1: Collection and Organization of data Hours: 8					
•	Graphical and pictorial presentation of data				
•	Measures of central tendency and dispersion				
•	Variance and standard deviation, relative error, coefficient of va	riation, pr	ecisior	n and	
	accuracy				
•	Sampling techniques: simple random sampling; stratification; es	stimation of	of the r	nean and	
	proportion.		1		
Unit 2	2: Probability		Hours: 6		
• Definition. Conditional probability and Bayes' theorem. Probability distributions: binomial, multinomial and Poisson distributions. Normal and lognormal distributions. Use of normal distribution tables.					
Unit 3	: Regression		Hou	rs: 6	
•	Linear regression and correlation, curvilinear regression, method	d of least s	quares	s, curve	
	fitting, Fiducial limits, probit and logit analysis		1		
Unit 4	: Parametric tests		Hou	rs: 8	
•	Testing hypothesis, Types of error. Level of significance. Signif	ïcance tes	ts and	p-value	
•	Tests of significance based on normal distribution, test of signifi	icance for	correla	ation	
	coefficients, confidence interval for mean and regression propor	tion			
Unit 5	: Nonparametric tests		Hou	rs: 4	
<ul> <li>Nonparametric procedures: Chi square goodness of fit test, sign test, MannWhitney test;</li> <li>Wilcoxon signed rank test</li> </ul>					
Unit 6	5: Experimental designs		Hou	rs: 8	

• Rar	idomization, completely randomized, randomized block and Latin sq	uare designs,
fact	orial design, cross over and parallel designs	
• Stu	dents should learn use of Minitab / R Software for data summary, co	rrelation,
reg	ression analysis, test of hypothesis and experimental design	
Research N	Iethodology	
Unit 7: Ob	jectives and purpose of Research	Hours: 2
• Typ	bes of research - Educational, clinical, experimental, basic, applied a	nd patent-oriented
rese	earch	
Unit 8: Lite	erature survey	Hours: 2
Use of libra	ry, books and journals, eJournals, retrieving patents and seeking repr	rints
Unit 9: Me	thods and tools used in research	Hours: 6
• Qua	alitiative and quantitative studies	
• Sin	ple data organization, descriptive data analysis	
• Lin	nitations and sources of errs	
• Inq	uiries in form of questionnaire, opinionaire or by interview	
• Sta	tistical analysis of data including variance, standard deviation, standa	urd error, mean,
stud	lent's t test and annova, correlation of data and its interpretation, con	nputer data
ana	lysis	
Unit 10: Sc	ientific writing and reporting	Hours:3
• Dif	ferent types of research papers	
• Titl	e and author names	
• Ab	stract and key words	
• Me	thodology	
Unit 11: Sc	ientific Presentation	Hours:3
• Imp	portance, types and different skills	
• Coi	ntent, format of model, introduction and ending	
• Ski	lls for oral presentation and types of visual aids	
• Que	estionnaire	
Unit 12: Pa	tents and Trade marks	Hours:4
• The	e Indian patent system	
• Pre	sent status of intellectual property rights (IPR)	
• Pro	duct patents and process patent	
• Rec	uirements and preparation of patent proposal	
• Reg	sistration of patent in foreign countries	
	Books:	
	16 Chromotographic methods by A Droithwaite & S. I. Smith Vily	van Aaadamia
Referenc	10. Chromatographic methods by A.Brathwate & S.J.Shitti, Kity	ver Academic
e	17 Thermal Analysis of Dhermacouticals by Craig Informa CBC	Drage Indian
- material·	Paprint Realized Craig, Informa, CRC	riess, mulan
	18 Practical Dharmacautical Chemistry by A U Daskatt and J.D. St	anlaka fourth
	adition part two CRS Publishers and Distributors	emake, ioufui
	10 Spectrometric Identification of Organic compounds by D M Sil	vorstoin
	13. Specifolieuro identification of Organic compounds by K.M.Sh	vei stem,

F.X.Webster, D.J.Kiemle, Latest edition, John Wiley & Sons
20. Applications of absorption spectroscopy of organic compounds by John Robert
Dyer
21. Organic Spectroscopy by William Kemp, PALGRAVE.
22. Textbook of Pharmaceutical Analysis by K.A.Connors, Wiley Interscience
Publications.
23. Introduction to Spectroscopy by D.L.Pavia, G.M.Lampman & G.S.Kriz.
24. Remington: The Science & Practice of Pharmacy, 20th edition, Vol. 1, Lippincot
Williams & Wilkins
25. Introduction to Modern Liquid Chromatography by L.R.Snyder, J.J.Kirkland 3 <sup>rd</sup>
edition.
26. Chiral separations by Liquid Chromatography and Related Technologies
Chromatographic Science Series by Hassan Y., Imran Ali, Vol. 90.
27. Static head space gas chromatography Theory & practice by Bruno Kolb &
L.S.Ettre.
28. Encyclopedia of Chromatography, by Jack Cazes, 3rd edition, Vol.1,2 & 3.
29. Online LC-NMR and Related techniques by Klasu Albert, John Wiley & Sons
30. LC-MS- A Practical Users guide, by Marvin C. McMaster.

Course: Advanced Pharmaceutical and Medicinal Chemistry (CBCS)						
Course Code: MPH_C_202_T	First Year M. Pharm		Semester: II			
Type of course: Theory	Contact Hours: 4 Hours/week (4L + 1T)		Contact Hours: 4 Hours/week (4L + 1T)		Total Contact 60	Hours:
Course assessment Methods:	Continuous mode of assessment		Semester assessm	-end ent		
Assessment Tool*:	Theory Sessional Attendance Exam		ment Tool*: Theory Sessional Exam Attendance End sem Examina		End seme Examina	ester tion
Max. Marks:	15 5 80					
Pre-requisites:	<ul> <li>Before undertaking the course, students should have knowledge of the following:</li> <li>1. Basics of enzymes as drug targets</li> <li>2. Basics of parameters of drug molecules responsible for steric, lipophilic and electronic factors.</li> <li>3. Biotechnological aspects in vaccine development.</li> </ul>					
Course Objectives:	<ul> <li>After completion of course students will be able to know:</li> <li>Various strategies to design and develop new drug like molecules for biological targets</li> <li>Statistical methods used in QSAR analysis and importance of statistical parameters</li> <li>Therapeutic values of Peptidomimetics</li> <li>Production of antisense agents</li> <li>Use of biotechnology in association with molecular biology and genetic engineering in production of drugs.</li> </ul>					
Course Outcomes: Upon completion of the course the student shall be able to:       PSO         PO Mapped       mapped         d       d				PSO mappe d		

CO1	Recall and relate the concept of enzyme kinetics and principles of enzyme inhibitors with the new advancements in medicinal chemistry with respect to synergism, biological activity of the molecule. Finding peptide synthesis and RNA structure to develop potential agents.	1, 2, 3,4, 9, 11	6, 8,	1, 2, 3	
CO2	Classify the type of enzyme inhibitors and interpret their nature of inhibition from the various plots of enzyme kinetics to explain and understand their molecular mechanism of inhibition and establish the relation with their IC50 and Ki values.	1, 2, 4, 5 8, 9, 11	, 6,	1, 2, 3	
CO3	Identify and make use of descriptors of molecules to develop an equation to quantitatively establish the structure activity relationship.	1, 2, 3, 4 8, 9, 10,	, 7, 11	1, 2, 3	
CO4	Apply the acquired knowledge in design of covalently and non-covalently binding enzyme inhibitors, peptidomimetics, antisense agents and biologicals based on converged fields of chemistry and biology.	1, 2, 3, 4 7, 9, 11	, 6,	1, 2, 3	
	Topics covered:	L			
Unit I:Enzyme InhibitionHours: 16					
<ul> <li>Coverage of basic aspects of enzyme kinetics, catalysis, transition-state theory.</li> <li>Drug Resistance through alterations of drug uptake, overproduction of enzyme, alterations of the enzyme active site, overproduction of the substrate or new pathways for formation of the product</li> <li>Drug synergism, concepts and mechanisms.</li> <li>Reversible enzyme inhibitors – competitive inhibition, non-competitive inhibition, uncompetitive inhibition with suitable examples. Detection of type of inhibition by suitable plotting methods. Concepts of IC50 and Ki.</li> <li>Slow-tight binding inhibitors, covalent enzyme inhibitors and mechanism-based inhibitors with suitable examples. Concept of Kinact and Ki for irreversible inhibitors</li> <li>Self-study of specific examples of different types of inhibitors, HIV protease inhibitors, aromatase inhibitors, DHFR inhibitors, viral DNA polymerase inhibitors, thymidylate synthase inhibitors and others).</li> </ul>					
•	Slow-tight binding inhibitors, covalent enzyme inhibitors and m inhibitors with suitable examples. Concept of Kinact and Ki for Self-study of specific examples of different types of inhibitors a examples like COX inhibitors, ACE inhibitors, RT inhibitors, H aromatase inhibitors, DHFR inhibitors, viral DNA polymerase i synthase inhibitors and others).	echanism- irreversibl nd their de IV proteas nhibitors, t	based le inhil esign (s se inhil thymid	bitors some bitors, lylate	
• Unit I	<ul> <li>Slow-tight binding inhibitors, covalent enzyme inhibitors and minhibitors with suitable examples. Concept of Kinact and Ki for Self-study of specific examples of different types of inhibitors a examples like COX inhibitors, ACE inhibitors, RT inhibitors, H aromatase inhibitors, DHFR inhibitors, viral DNA polymerase i synthase inhibitors and others).</li> <li>QSAR</li> </ul>	echanism- irreversibl nd their de IV proteas nhibitors, t	based le inhit esign (se inhit thymid <b>Hour</b>	bitors some bitors, lylate rs: 14	

\_\_\_\_\_

erro	error, validation methods like cross-validation by calculation of q2, boot-strap analysis and randomization. Application domain for predictions using a OSAR model						
	sign of training and test sets using factorial design	uei.					
• Sel	f-Study – Different types of descriptors reported in literature that	account for the					
ster	ic. electronic and lipophilic effects.	decount for the					
Unit III:	Peptides and Peptidomimetics	Hours: 14					
• Coverage of peptide structure, biosynthesis of peptides and solid-phase/solution synthesis of peptides.							
• Design of peptidominetics by manipulation of the amino acids, modification of the peptide backbone, incorporating conformational constraints locally or globally, $\alpha$ -helix, $\beta$ -sheet $\beta$ -and $\gamma$ -turn mimetics							
• Sel CC	f-study of examples of peptidomimetics for some enzymes and rece K, bradykinin	ptors like ACE,					
Sel     CC	f-study of examples of peptidomimetics for some enzymes and rece K, bradykinin	ptors like ACE,					
Unit IV:         Antisense therapeutic agents         Hours: 6							
<ul> <li>His</li> <li>Deservation</li> <li>example</li> </ul>	tory and principles sign of antisense oligonucleotides and small interfering RNAs (siRM mples	NAs) with some					
Unit V:	Molecular Biology, Genetic engineering and Biotechnology	Hours: 6					
• Mo	lecular Biology, Genetic engineering and Biotechnology in productio	n of biologicals					
• Sel	f-study of biotechnology-based drugs, vaccines and diagnostic agents	s with respect to					
the	ir biological source, their design and the mechanism of their actions						
	Books:						
	1. The Organic Chemistry of Drug Design and Drug Action, S Academic Press.	Silverman R. B.,					
Referenc	2. Textbook of Drug Design and Discovery, Eds. Krogsgaard-Larsen P.,						
e	Liljefors T., Madsen U., Taylor & Francis.						
material:	3. Medicinal Chemistry: An Introduction, Thomas G, Wiley.	tions Ed Ionson					
	4. replue and rioleni Design for Diopharmaceutical Applicat K I Ch 3 Aspects of Pentidomimetics by Mass V. Tourwe	A D John Wiley					
	& Sons, Ltd. Chichester, UK.	D., John Whey					
	5. Comprehensive Medicinal Chemistry, Series Ed., Hansch Press	1 C., Pergamon					
	6. Burger's Medicinal Chemistry, Drug Discovery and Develop	ment, Wiley.					

	Course:Advanced Organic Chemistry (CBCS 2016)							
Cou MPH	I <b>rse Code:</b> I_C_203_T	First Year M. P	harm	Semest	ter: II			
Type of course: Theory		Contact Hours: 4 Ho	urs/week (3L +	· 1T)	Total	Contact Hours:60		
Cours Metho	e assessment ods:	Continuous mode of a	assessment	Sei	nester-0	end assessment		
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End	End semester Examination			
Max. I	Marks:	15	5			80		
		Students should recollect	basic reactions	of organ	nic chen	nistry and should		
Pre-requisites:		Student should possess ki stereochemistry and biolo Students should have thro methods for organic comp	have understanding of how to write reaction mechanism stepwise. Student should possess knowledge related to basic concepts of stereochemistry and biological significance of chiral medicinal drugs. Students should have through understanding of conventional synthetic methods for organic compound.					
Cours	e Objectives:	To provide in-depth knowledge about advances in organic chemistry, different techniques of organic synthesis and their applications to process chemistry as well as drug discovery. To understand concepts of synthon approach						
Cours the lea	e Outcomes: U Arner would b	Upon completion of the cu e able to:	PO Ma	apped	PSO mapped			
CO1	Learn and ap stereochemis	ply advanced concepts of ty		1,3,4,8	,10,11	1,2		
CO2	Understand and explain basic concepts of Catalysis, its types and different reactions of organometallic compounds.			1,3,4,8	,10,11	1,2,3		
CO3	Understand the restrosynthetic methods and apply the knowledge of reactions covered for predicting retrosynthetic pathways of newer drugs			1,3,4,8	,10,11	1,2		
CO4	Apply and integrate acquired concepts of asymmetric synthesis in synthesis of chiral medicinal			1,3,4,8	,10,11	1,2,3		
CO5	Understand t combinatoria	he merits and techniques i Il synthesis	involved in	1,3,4,8	,10,11	1,2,3		
CO6	Understand v and compare synthesis	approaches Il methods of	1,3,4,8	,10,11	1,2,3			

	Topics covered:						
Unit I:	Advanced Stereochemistry	12					
<ul> <li>Self Study - Coverage of the basic concepts in stereochemistry –optical activity, specific rotation, racemates and resolution of racemates, the Cahn-Ingold-Prelog sequence rule, meso compounds, pseudo asymmetric centres, pro-R, pro-S, axes of symmetry, Fischers D and L notation, cis-trans isomerism, exoendo, syn-anti nomenclature. Stereoselective and stereospecific reactions. Conformational isomerism in acyclic systems. Shape of six membered rings and effect of substituents and reactivity.</li> <li>Chirality in systems lacking a stereogenic carbon atom</li> <li>Point chirality – tertiary amines and phosphines</li> <li>Axial chirality – allenes, biphenyls and binaphthyls</li> <li>Helical structures – polynucleotides, polyamino acids, biaryls and Allenes</li> <li>Methods for estimating ratios of stereoisomers in a mixture, separation and identification of the individual components by NMR spectroscopy, X-ray crystallography</li> <li>Nucleophilic attack on acyclic carbonyl compounds – Cram's rule, Felkin-Ahn rule. Locking effects in nucleophilic reactions at carbonyl groups Stereochemistry of important reactions leading to formation of alkenes – Wittig and related reactions</li> </ul>							
Unit II:	Catalysis & Organometallics in Organic Synthesis	12					
<ul> <li>Unit II: Catalysis &amp; Organometallics in Organic Synthesis 12</li> <li>Types of catalysis, heterogeneous and homogenous catalysis, advantages and disadvantages, catalytic cycles</li> <li>Heterogeneous catalysis – preparation, characterization, kinetics,</li> <li>supported catalysts, catalyst deactivation and regeneration, some examples of heterogeneous catalysis used in synthesis of drugs.</li> <li>Homogenous catalysis, hydrogenation, hydroformylation, hydrocyanation, Wilkinson catalysts, chiral ligands and chiral induction, Ziegler-Natta catalysts, some examples of homogenous catalysis used in synthesis of drugs</li> <li>Phase transfer catalysis - theory and applications</li> <li>Introduction, Classification of organometallic compounds based on hapticity and polar of the M-C bond. Nomenclature and general characters. Synthesis, stability and decomposition pathways.</li> <li>Transition metal π-complexes with unsaturated organic molecules, carbon monoxide, alkenes, alkynes, allyl, dienes, cyclopentadienyl, arene complexes, preparation, proper nature of bonding and structural features, important reactions relating to nucleophilic attack on ligands and to organic synthesis. Basic organometallic reactions covering oxidative reactions, migratory reactions, insertions, extrusion, additions, eliminations their mechanisms and stereochemistry.</li> <li>Self Study - Basic organometallic reactions covering oxidative</li> </ul>							
Unit III:	Synthon Approach and Applications	Hours: 13					
R     d     d     C     1     S     S     S     S	etrosynthesis and its advantages, rules for dissection of molecules, meaning isconnection, FGI, FGA and synthons, guidelines for the order of events -X disconnections; C-C disconnections – alcohols and carbonyl compoun ,4-, 1,5-, 1,6-difunctionalized compounds trategies for synthesis of three, four, five and six-membered rings trategies for synthesis of aromatic and saturated heterocycles <i>elf Study – Strategies for synthesis of saturated heterocycles</i> .	ng of the term, ds; 1,2-, 1,3-,					

Unit IV:	Asymmetric Synthesis	Hours: 6
• Intr	oduction and need; chiral synthesis using chiral pool, chiral auxiliaries,	chiral catalysts
• Enz	zymes, chiral solvents and whole organisms	
• An	alytical methods of determining purity of stereoisomers	
• Sel	Combinatorial Chamistry	Hourse 11
	Combinatorial Chemistry	Hours: 11
<ul> <li>Introdu</li> <li>Solid n</li> </ul>		
• Solid p	ta linkors, and tags	
<ul> <li>Suppor</li> <li>Decent</li> </ul>		
Deconv     Deconv	olution and iteration	
• Parallel	synthesis, multistep – convergent and sequential synthesis.	
• Self Stu	dy – Multicomponent reactions	
Unit VI:	Green Chemistry	Hours: 5
• Histor	y, need and the goals of green chemistry	
• Basic	principles of green chemistry, illustrated with examples to discuss issues	s of prevention
of was	te or minimize by-products, atomeconomy, prevent and minimize forma	ition of
hazard	ous or toxic products, design of safer chemical equivalents, selection of	appropriate
microx	us, media, separation agents, improve economy and efficiency of reactions	lis, by use of
• Self St	udy – Reactions carried out using Microwave and ultrasound.	
~	Books	
	1. Stereochemistry of carbon compounds, Eliel E. Wilen S H. Manden	L N. Wiley.
	2. Stereochemistry of Organic Compounds, Nasipuri D, Wiley Eastern	1.
	3. Advanced Organic Chemistry, Carey FA and Sundberg RJ, Part A a	und B, Springer
	4. Introduction to Green Chemistry, Ryan M. A., Tinnesand M., Ame	rican Chemical
	Society (Washington).	
	5. Combinatorial Chemistry; Synthesis and Application, Eds., Wilson	S. R. Czarnik
	A. W. Wiley: New York.	) wford
	University Press	VXIOIU
	7 Stereoselective Synthesis Atkinson R S John Wiley & Sons	
Reference	8. The Organometallic Chemistry of the Transition Metals, Crabtree F	R. H., John
material:	Wiley	
	9. Transition Metals in Synthesis of Complex Organic Molecules, He	gedus L.,
	University Science Books.	
	10. Homogenous Transition Metal Catalysis, Masters C., Chapman &	Hall.
	11. Principles and Practice of Heterogenous Catalysis, Thomas J. M.,	I nomas M. J.,
	12 Principles of Asymmetric Synthesis Gawley R. F. Aubrey I. Flee	vier
	13. Greene's Protective Groups in Organic Synthesis. Wuts. P. G. M.	Green T. W.
	Wiley	,
	14. Organic Synthesis - The Disconnection Approach, Stuart, W., Wil	ey.
	15. The logic of chemical synthesis, Corey E J and Cheng X-M, John	Wiley and

	Course: Advanced Pharmaceutics I (CBCS Revised 2016)								
Course Code: MPH_C_204_ T		First Year M. Pharm			Semester: I				
Type of Th	f course: eorv		Contact Ho	urs: 4 Hours/v	week (4L)		Total Contact Hours: 60		
Course Method	assessme ls:	nt	С	ontinuous mo	de of assessm	ent	Semester		r-end nent
Assessr	nent Tool	*•	Theory Sessional Exam	Attendance	Three Academic Activities	T in	Feacher -End semesStudentExaminati		nester ation
Max. M	larks:		15	4	3		3	75	
Pre-rec	quisites:	Shoul pharm	d have know naceutical ma	ledge of recent arket trend.	advances in 1	new	drug deliv	very systems an	ıd
Course Objecti	ives:	The condevelo	ourse aims to opment and e	o impart a higher evaluation of ac	er level of the lvanced drug	oret deli	tical up to very syste	date knowledge ms.	e in design,
<b>Course Outcomes</b> Upon completion of the course, the students will be able to					PO Mapped		PSO mapped		
CO1	Understand the acquire insight system and mac		e recent advances in tablet technology. Will t to oral controlled release drug delivery chinery used for the same.			1,3	,5,6,9,11	1, 3	
CO2	Familiari delivery evaluatic and stud release a	ze with system on of sr by the nd long	h the recent advances in particulate drug as, provide an insight to formulation and mall volume and large volume Parenterals recent advances in injectable controlled g acting formulations		1,3	,5,6,9,11	1,3		
CO3	Will be in the phase system of the second se	introduo stems.	ced to specia	lized pharmac	eutical disper	se	1,3	,5,6,9,11	1,3
CO4	Understand the recent advances in gastro retentive oral drug delivery systems, concepts and various types of oral controlled release drug delivery system and evaluation methods for the same				1,3				
CO5	<ul> <li>Acquire knowledge on site specific drug delivery systems</li> <li>5 Acquire knowledge on site specific drug delivery systems</li> <li>5 to increase therapeutic efficacy of drug with minimum side-effects. Understand physiology of eye and develop advancements in ocular controlled drug delivery systems</li> </ul>				1,3				
cosside-effects. U advancements iAcquire knowled to increase ther side-effects. Ur anatomy of skin delivery system guidelines. Perco obtain safe, effects			dge on site sp peutic effica derstand in d , recent deve s and evaluat eive knowled ctive and rep	pecific drug de cy of drug with etail biochemis lopments in tra e TDDS as per lge on Quality roducible form	livery systems a minimum stry and insdermal drug regulatory by design to nulations (as p	g er	1,3	,5,6,9,11	1,2,3

	Topics covered:						
Unit I:	Solids – oral SR system	Hours: 13					
Over Rele Rese bucc sphe	<ul> <li>Overview of Single oral unit SR systems, Structure and physiology of GIT, Mechanism of Release &amp; Release kinetic equations. Types – Diffusion controlled, Dissolution controlled, Reservoir, Matrix, Osmotic systems, Ion exchange systems Mucosal drug delivery systems- buccal, gingival, sublingual. Multiparticulate systems-pelletization (emphasis on extrusion and spheronization). Orodispersible systems. Pulsatile Drug delivery systems</li> </ul>						
Unit II:	Parenteral SR systems	Hours: 12					
<ul> <li>Need poly solut conc pum relea</li> </ul>	d and concept, routes employed, Approaches- aqueous systems mers), aqueous suspensions (depot injections, microspheres, magne- tions & suspensions, Emulsions (Microemulsions, multiple emulsion ept, properties desired, various approaches), prodrugs (chemical p ps, Biopharmaceutical aspects, Sterilization & stability issues, C use studies, Issues related to Safety, Toxicity & Tissue Injury	(complexation, use of etic microspheres), Oily ns,), Implants (in detail- modifications), infusion Characterization wrt on					
Unit III:	Specialized Emulsions	Hours: 9					
Micr Form App	coemulsions, Multiple emulsions, Self Emulsifying Drug Delivery nulation and phase behaviour; Preparation & Characterization; lications, Theories of Emulsification, Factors influencing type of emu	systems & SMEDDS; Bioavailabity Aspects; lsion formed.					
Unit IV:	Gastro-retentive Drug Delivery Systems	Hours: 8					
Intro     Gast     dens     syste	ro-retention; concept of absorption window; need for GRDDS, gastric ro-retention; Factors controlling performance of GRDDS. Differ ity systems, floating systems, mucoadhesive systems, Expanda ems, Superporous Hydrogels, Evaluation.	rent Approaches- High ble systems, Magnetic					
Unit V:	Ocular drug delivery systems.	Hours: 7					
Stru     ocul     inset     prod	acture and physiology of eye; Drug absorption and disposition in the or ar drug residence with emphasis on mucoadhesive systems. Intraocu ts / Erodible inserts. Novel ophthalmic drug delivery systems, Nanop rugs. Ocular penetration enhancers.	eye. Methods to prolong llar inserts; Nonerodible particles, liposomes and					
Unit VI:	Transdermal Drug Delivery Systems	Hours: 7					
Strue pene eval trans	cture and physiology of skin. Principles of skin permeation. Kinetic stration enhancers. Types (Gels, Patches/films), Pressure sensitive adl station – in vitro, in vivo. Iontophoresis, Recent advances –u stdermal drug delivery.	es of skin permeation & hesives, Development & se of microneedles in					
Unit VI:	Introduction to Pharmaceutical Processing Development.	Hours: 4					
Elen Link Con Phan	• Elements in Pharmaceutical development- Target product profile, Critical Quality Attributes., Linking Material Attributes & process parameters to CQA's Risk Assessment Design space, Control Strategy, Product Lifecycle management & continual improvement. Submission of Pharmaceutical Development and related information in CTD format.						
Reference material:	<ol> <li>Targeted and Controlled Drug Delivery: Novel Carrier Syst RK, CBS Publishers and Distributors, 1stedn, 2002.</li> <li>Controlled and Novel Drug Delivery by Jain NK, Distributors, 2008.</li> <li>Controlled Drug Delivery: Fundamentals and Application VHL, Dekker, 2 ndedn, Vol 29, 1987.</li> <li>Novel Drug Delivery System by Chien YW, 2ndedn, Vol</li> </ol>	CBS Publishers and ns by Robinson JR, Lee 50, Informa Healthcare,					

2003.
5. Progress in Controlled and Novel Drug Delivery Systems by Jain NK, CBS
Publishers and Distributors; 2004.
6. Ophthalmic Drug Delivery Systems, Mitra AK, 2nd edn., Drugs and
Pharmaceutical Sciences Series, Vol. 130, Marcel Dekker, 2003.
7. Polymeric drug delivery system, Kwon GS, Marcel Dekker, Vol 148, 2005.
8. Nanoparticulate Drug Delivery System by Thassu D, Deleers M, Pathak Y, Marcel
Dekker, Vol 166, 2007.
9. Controlled Drug Delivery- Challenges and Strategies by Park K, American
Chemical Society, 1997.
10. Colloidal Drug Delivery System by Kreuter J, Marcel Dekker Vol 66, 1994. 11.
www.ich.org
12. Pharmaceutical Dosage Forms: Disperse Systems by Lieberman HA, Rieger
MM, Banker GS, Marcel Dekker, Vol 3, 2nd edn, 2005.
13. Pharmaceutical Emulsions and Suspensions by Nielloud F, Marti- Mestres G,
Marcel Dekker, Vol 105, 2000.
14. Controlled Release Systems Fabrication Technology by Dean STH, CRC Press,
Vol 1, 1988.
15. Bioadhesive Drug Delivery Systems by Mathiowitz.E, Chickering DE, Lehr
CM, Marcel Dekker Vol 98,1999.
16. Pharmaceutical Skin Penetration Enhancement by Walters. K A, Hadgraft J,
Marcel Dekker, Vol 59, 1993.
17. Percutaneous Absorption by Bronaugh RL, Maibach HI, Taylor and Francis, 3rd
edn, Vol 97, 2005.
18. Transdermal Controlled Systemic Medication by Chien YW, Marcel Dekker,
Vol. 31, 1987.
19. Oral Mucosal Drug Delivery by Rathbone MJ, Marcel Dekker, Vol 74, 1996. 20.
Modified Release Drug Delivery Technology by Rathbone MJ, Hadgraft J, Roberts
MS, Lane ME, Informa Healthcare, 2nd edn, Vol 183(1), 2008.
21. Pharmaceutical Pelletization Technology, Ghebre-sellassie. I, , Marcel Dekker,
Vol. 37

Course: Advanced Pharmaceutics II (CBCS Revised 2016)									
Cours MPH_0	e Code: C_205_T		First	Year M. Pha	rm	Semester	:: I		
Type of course: Theory		Contact Ho	urs: 4 Hours/	week (4L)	Total Co	ntact Hours:	60		
Course Method	assessment s:	t	С	ontinuous mo	de of assessm	ent	Semester-end assessment		
Assessm	ent Tool*:	:	Theory Sessional Exam	Attendance	Three Academic Activities	Teacher - Student interaction	'eacher - Student iteractionEnd semester Examination		
Max. M	arks:		15	4	3	3	75	5	
Pre-req	uisites:	Shou pharm	ld have know naceutical ma	ledge of recent arket trend.	t advances in 1	new drug deliv	very systems a	ind	
Course Objectiv	ves:	The c desig	ourse aims to n, developme	o impart a highe ent and evaluati	er level of the	oretical up to ored drug deliver	date knowledg ry systems.	ge in	
<b>Course Outcomes</b> Upon completion of the course, the students will be able to				PO N	PO Mapped PS map				
CO1	Understan therapeut Will kno and recen	nderstand site specific drug delivery systems to increase erapeutic efficacy of drug with minimum side-effects. ill know specialized pharmaceutical dispersed systems d recent advances in particulate drug delivery systems			1, 3				
CO2	Understan lungs. Ha and pulme	nd anat ave kno onary c	omy and ph owledge on lrug delivery	ysiology of na recent develop systems and its	sal mucosa and mucosa and mucosa and sales and sa	nd 1,3,5 sal	1,3,5,6,9,11 1,3		
CO3	Understar peptides developm	nd the and pro lents in	structural contain delivery peptide base	omplexity and y of drugs and d drug delivery	l challenges develop rece y systems.	to 1,3,5 ent	5,6,9,11	1,3	
CO4	Gain kno delivery s	wledge systems	e on recent	advances in p	particulate dr	ug 1,3,5	5,6,9,11	1,3	
C05	Acquire knowledge on site specific drug delivery systems to increase therapeutic efficacy of drug with minimum side- effects. Understand physiology of brain, its barriers and develop advancements in brain controlled drug delivery systems       1,3,5,6,9,11       1,3								
				Topics co	overed:				
Unit I:	Targ	geted sy	stems:-Activ	e and Passive a	approaches:		Hours: 6		
•	Concepts a molecular ( Ligands as	and rat events deliver	ionale of tan in drug targ y and targeti	geting: active eting. Tumour ng tools, Conce	and passive targeting, Mo ept of receptor	targeting, Ce olecular target mediated end	llular biochei ts for cellular locytosis	nistry and targeting,	
Unit II:	Puln	nonary	and nasal dru	ig delivery syst	tems:		Hours: 14		
•	<ul> <li>Anatomy and physiology of the respiratory system, Airway physiology and disposition patterns</li> <li>Nasal drug delivery: Nasal administration – dosage forms, Strategies for enhancement in nasal absorption, Animal models for nasal absorption studies, Nasal preparations for systemic effect</li> </ul>								

• Pulmonary drug delivery : Factors affecting particle disposition in the lungs, Dosage forms for							
pulmonary drug delivery (Nebulizer, Metered dose inhalers, Dry powder inhaler	rs), Drug						
targeting to the respiratory tract, Pulmonary receptor targeting							
Unit III: Protein and peptide drug delivery systems: Hours: 11							
• Structure of proteins and peptides, analysis of proteins and peptides Physical and	chemical						
pentides barriers to transport and approaches to circumvent metabolic barriers. Gener	al protein						
formulation and delivery system strategies. Routes for delivery of proteins and pept	ides with						
emphasis on oral and mucosal delivery, pulmonary delivery, nasal delivery and	parenteral						
delivery	-						
Unit IV:Colloidal drug delivery systems:Hours: 22							
• Introduction, comparison with other colloidal drug carriers, Advantages/limitations, co	nstituents						
and mechanism of formation, method of preparation and drug loading, characteris	ation and						
evaluation, stability, long circulating / modified form of colloidal drug carrier, bio di	stribution						
Biopharmaceutical aspects Liposomes Niosomes Nanoparticles SLNs Polymeric mic							
Unit V: Brain targeting Hours: 7	enes						
• Introduction, Blood brain barrier, CSF barrier, limitations in brain uptake of drug	, desired						
physicochemical characteristics of drugs. Transport through BBB, Factors affect	ing drug						
permeation through BBB, Brain drug delivery strategies: Invasive- Intracerebral	implants,						
Intraventricular infusion, BBB disruption, Non-invasive techniques- Chemical method,	Colloidal						
drug carrier, receptor/vector mediated approach. Miscellaneous techniques- Intranasal	etc						
Reference material:	CDC						
1. Targeted and controlled drug delivery: Novel carrier systems- by S. P Vyas and R. K Kha	r, CBS						
publishers and distributors pvt Ltd.							
2. Advances in controlled and novel drug delivery edited by N.K.Jain, CBS publishers and							
distributors pvt Ltd.							
3. Robinson J.R and Lee- controlled and novel drug delivery.							
4. Controlled drug delivery: Concepts and advances, S.P.Vyas, R.K. Khar, Vallabh Prakasha	n.						
5. Chien- Y. W- Novel Drug Delivery System, Drug and pharmaceutical science series, Vol	14, New						
York Inc, Marcell Dekker.							
6. Controlled and novel drug delivery edited by N. K. Jain, CBS publishers and distributors j	ovt Ltd.						
7. Advances in pharmaceutical sciences – vol-1 to 5, by H. S. Bean and A. H Beckett.							
8. Glen S. Kwon, Polymeric drug delivery system- Marcell Dekker Series , Vol 148, P.No.5.	8. Glen S. Kwon, Polymeric drug delivery system- Marcell Dekker Series , Vol 148, P.No.533-560						
9. Thassu D "Nanoparticulate Drug Delivery System" Vol 166, Marcell Dekker Series 2007.							
10. Park K, Control Drug Delivery- Challenges and Strategies, CRC, Washington DC 1997							
11. MacNally E "Protein Formulation and Delivery" 2nd edition, Vol75, 2008 12. Kreuter J,							
Colloidal Drug Delivery System, Vol.66, Marcell Dekker, Inc New York, 1994							

Course: Quality Assurance System (CBCS)							
Cou MPI	ırse Code: H_C_212_T	First	Semester: II				
Type of Theor	of course: y	Contact Hours:	4 Hours/week (3L + 1T)	Total Contact I	Hours: 60		
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Semester assessm	-end ent		
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End seme Examina	ester tion		
Max.	Marks:	15	5	80			
Pre-re	equisites:	Basic understandir thus improve the q	ng of validation and how it can uality of the products.	be applied to inc	lustry and		
Cours	e Objectives:	Upon completion of Understand the con qualification of var different dosage for drugs, Cleaning var pharmaceuticals.	of this course, it is expected that neepts of calibration, qualificat rious equipment and instrumen orms, Validation of analytical n ilidation of equipment employe	at students will be ion and validation its, Process valid nethod for estimated in the manufact	e able to on, the ation of ation of cture of		
Cou	rse Outcomes	Upon completion of be able to:	of the course the student shall	PO Mapped	PSO mappe d		
CO1	Understand th calibration	ne concept of validat	tion, qualification and	1,2,3,4,8, 11	1		
CO2	Describe proc equipment	cedure for qualificati	ion of instruments and	1.2.3.4	1		
CO3	Summarize t method valid	he parameters of IG ation.	CH guidelines for analytical	1, 11	3		
CO4	Comprehend dosage forms	the concept of proce	ess validation of different	1,2,3,4,5, 6,7,8	1		
CO5	Gain knowled	Gain knowledge of the process of cleaning validation			2		
CO6	O6Correlate the knowledge of IPR with respect to pharmaceutical products1,2,3,4,7, 8,113				3		
	Topics covered:						

Unit 1: R	egulatory basis for validation	Hours: 5						
• U:	• US FDA guidelines (cGMP guidelines, 21 CFR 210-211), EU guidelines, WHO							
gu	iidelines.							
Unit 2: Te	erminology and validation overview	Hours: 10						
• Se	ation.							
• Co	oncepts of DQ, IQ, OQ and PQ							
• Co	oncepts of Prospective validation, retrospective validation, Concurrent and	nd revalidation.						
Va	alidation Master Plan.							
Unit 3: Va	alidation of Equipment	Hours: 10						
• Di	ry Powder Mixers							
• Fl	uid Bed and Tray dryers							
• Ta	ablet Compression Machine							
• Se	elf-study: Dry Heat Sterilization/Tunnels							
• A	utoclaves							
• Ca	apsule filling machines							
• Va	alidation of Integrated lines by media fill test							
Unit 4: Ut	tilities Validation	Hours: 7						
• Va	alidation of Pharmaceutical Water System & pure steam							
• Va	alidation of HAVC system							
• V:	alidation of Compressed air							
Unit 5: Cl	leaning Validation	Hours: 4						
• Se	elf-study: Cleaning of Equipment, Cleaning of Facilities							
Unit 6: A	nalytical Method Validation	Hours: 6						
• G	eneral principles of analytical method validation, Validation of following	g analytical						
In	struments: HPLC, Dissolution test apparatus, U.V./Visible spectrophoto	meters						
Unit 7: Pr	rocess Validation	Hours: 13						
• Se	elf-study: Prospective, concurrent, retrospective & revalidation Self-stud	У						
• Pr	cocess validation of following formulations: Uncoated / Coated tablets, H	lard gelatin						
Ca	apsules, Ampoules & Vials, Self-study: Ointment/Creams, Self-study: L	iquid Orals,						
Tı	ransdermal patches (Matrix systems)							
Unit 8: manufact	Self-Study-Computer system validation in controlling the uring process.	Hours: 2						
Unit 9: I	Process Analytical Technologies (PAT) and Quality by Design	Hourse 3						
(QbD) (U	S FDA)	Hours. 5						
	Books:							
D C	1 Validation and Qualification in Analytical Laboratories by Ludw	ig Huber						
Referenc	Second edition (2007) Informa Health Care, New York, London							
e	2. Pharmaceutical Process Validation by R Nash and Wachter Volu	ime 129. Latest						
material:	edition. Marcel Dekker Inc. New York							
	3. GMP for Pharmaceuticals by Sidney H. Willing, Fifth edition M	arcel Decker						
	Series, New York.							

	4.	United States Pharmacopoeia & Indian Pharmacopoeia.
	5.	Validation of Pharmaceutical process, F. J. Carleton and J. Agalloco, Marcel
		Dekker Inc.

Course: Pharmaceutical Quality Management (CBCS)						
Cou MPH	ırse Code: H_C_213_T	First	First Year M. Pharm			
Type o Theor	of course: y	Contact Hours:	4 Hours/week (3L + 1T)	Total Contact H	Hours: 60	
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Semester assessm	-end ent	
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End seme Examina	ester tion	
Max.	Marks:	15	5	80		
Pre-re	equisites:	Basic knowledge of industry.	f pharmaceutical manufacturin	ng planning, proc	cesses and	
Cours Cou	e Objectives: arse Outcomes	Upon completion of understand- 1. Th 2. IS 3. To 4. An 5. Qu 6. St 7. St : Upon completion of be able to:	of the course, it is expected that ne importance of quality O management systems bols for quality improvement nalysis of issues in quality uality evaluation of pharmaceu ability testing of drug and drug atistical approaches for quality of the course the student shall	t students will be ticals substances <b>PO Mapped</b>	PSO mappe d	
CO1	Understand th management management	ne concept of quality and define different systems.	y, strategic quality terms involved in quality	1,2,5,6	1,3	
CO2	Understand the concept of statistical process control (SPC) and explain the principles involved in SPC like process capability, control chart analysis and process control.			2,3,4,5,11	1,3	
CO3	Recognize the required to a the developm the different benchmarking	gnize the importance of customer, different concepts red to achieve customer satisfaction and desired quality evelopment of quality culture and define and comprehend different terms, types and process involved in marking.			3	
CO4	Comprehend management	principles involved i like six sigma, ISO,	in pharmaceutical quality WHO-GMP and CFR-21.	2,3,4,5,6,7,10	1,2	

CO5	Apply ICH guidelines for drug stability, risk management and	1,2,3,5,8	8,9	1,3
	quality by design.			
	Topics covered:			
Unit 1	: Concept of-		Hou	rs: 8
•	Total Quality Management (TQM), Quality control and quality a	assurance,	Quali	ty control
	laboratory responsibilities. Self-study: Good laboratory practices	5		-
Unit 2	: GMP		Hou	rs: 8
•	Organization of pharmaceutical manufacturing unit, production self-study: Revised schedule M	manageme	nt,	
Unit 3	: Personnel:		Hou	rs: 12
•	Self-study: Introduction, Human resource development, Qualific Training, Responsibility, Personl Hygiene & Grooming. Location, Plant layout, Lighting, Sewage, Water Handling-Sewa Washing and toilet facility, Sanitation, Controls of contaminatio controlstics. Personal Hygiene and Gowning	ation Expe ge, Refuge n and Envi	erience e and l ronme	e and Disposal, ental
Unit 4	: Materials Management:		Hou	s: 8
•	API's, raw materials & packaging materials, Purchase specificat	ions, Selec	tion c	of
	vendors, Intermediates & Finished products, Rejected and Recov	vered mate	rials,	Recalled
	products, Reagents & culture media, Reference standards, Waste	e materials		
•	Warehousing- Good Warehousing Practices, distribution and rec	ords		
Unit 5	: Manufacturing Operations and Control:		Hou	rs: 8
٠	Self-study: Sanitation of Manufacturing Premises, Line clearanc	e, Mix-ups	and (	Cross
	contamination, Processing and holding of Intermediates and Bul	k Products		
•	Packaging, I.P.Q.C., Release and storage of Finished Product, Prod	cocess Dev	iation	s and
	Incidents, Drug product inspection, Yield calculations			
•	Expiry dating, Manufacturing record review and approval			
Unit 6	: Documentation and Records:		Hou	rs: 6
•	In-process and Product Release Specifications, Master production	n and cont	rol re	cord,
	Batch production and control record, Standard Operating Proced	ures (SOP)	), Cha	nge
	Control, Site master file			
Unit 7	: Post Operational Activities:		Hou	rs: 5
•	Distribution, Complaints and recalls, evaluation of complaints, F	Recall proc	edure	s, related
	records and documents			
•	Outsourcing: Facility audit, Manufacturing, Packaging, Analytic	al, Clinica	land	other
	services outsourcing.			
Unit 8	: Site and Plant security:		Hou	rs: 2
•	Security personnel, Entry procedures to site & plant, Internal sec Fuel storage, Canteen & cooking, Garden & horticulture	curity, Veh	icle p	arking,
Unit 9	• Audits:		Нош	·s: 3
•	Principle of Quality audit, Plant level, Department wise docu	mentatior	1	

	Books:
	<b>1.</b> Quality Assurance of Pharmaceuticals, Vol. 2, Updated Edition, World Health Organization, Geneva.
	2. S.H. Willing, Good Manufacturing Practices for Pharmaceuticals; A plan for total
Referenc	Quality control, Latest Edition, Marcel Dekker.
е	
material:	3. Regulatory guidelines related to GMP by:
	a. 21 Code of Federal Regulation, Parts 210, 211&58 (USFDA guidelines)
	b. EU, MHRA, UK Guidelines on GMP
	c. Schedule M of Drug & Cosmetics Act.
	4. Quality Planning & Analysis by J. M. Juran and F. M. Gryna, Tata Mcgraw Hill,
	India.
	Quality Assurance Guide by Organization of Pharmaceutical Producers of India.

Course: Drug Metabolism (CBCS)						
Course Code: MPH_C_217_T		First Year M. Pharm			Semester: II	
Type of course: Theory		Contact Hours:	4 Hours/week (4L + 1T)	Total Contact Hours: 60		Hours: 60
Course assessment Methods:		Continuous	s mode of assessment	Semester-end assessment		-end ent
Asses	sment Tool*:	Theory Sessional Exam	Attendance	End semester Examination		
Max.	Marks:	15	5		80	
Pre-r	equisites:	<ul><li>Basic know</li><li>Concept of</li></ul>	vledge of anatomy and physio FADME	logy of liv	er and	kidney
Cours	se Objectives:	Upon completion o	of the course the student will b	e able to p	redict	the
Course Outcomes		: Upon completion of the course the student shall be able to:		PO Mapped		PSO mappe d
CO1	Recall the con metabolism a	ncept of drug metabo nd in silico drug met	blism, types of drug abolism prediction	1, 2, 3, 7 11	', 8,	1, 2, 3
CO2	Explain and i through prime	llustrate the mechani ary and secondary pa	ism for metabolism of drugs athways	1, 2, 3, 4 7, 11	, 6,	1, 2, 3
CO3	Application metabolism a	of the gained know nd metabolic profilir	wledge in basic studies on ng	1, 2, 4, 6 8, 11	5, 7,	1, 2, 3
		Т	<b>Copics covered:</b>	1		
Unit 1:Introduction to xenobiotic/drug metabolismHours: 6				rs: 6		
•	Introduction (Physical bar Types of read bioactivation factors affect	to xenobiotic/drug m riers, excretion, imm ctions (I and II), cons , prodrugs], organs o ing drug metabolism	etabolism and its relation to o nune system). requences of drug metabolism f DM, localization of drug me	ther 2 defe (DM) [ina tabolizing	ense sy activati enzym	stems on, nes,
Unit 2	2: Cytochro	ome P450s			Hou	rs: 20
•	<ul> <li>Introduction to the family of enzymes, their classification and nomenclature</li> <li>Introduction to the family of enzymes, their classification and nomenclature</li> </ul>					

	P450 catalytic cycle, different types of reactions catalyzed by CY	P450s and the			
me	mechanisms of catalysis				
• Hu	man CYP450s involved in DM, their distribution and properties, typ	pical substrates,			
spe	ecific probe substrates, specific inhibitors, induction of CYPs and specif	fic inducers			
• Ge	netic polymorphism in CYP450 expression				
Unit 3:	NON P450 enzymes	Hours: 20			
• Int	roduction to NON P450 enzymes involved in drug metabolism	•			
• Self-study of NON P450s - glucuronosyltransferases, sulfotransferases, glutathione S-					
tra	nsferases. N-acetyl transferases, xanthine oxidase, aldehyde oxidase, es	terase, epoxide			
hv	drolase nitro/azo reducatases and FMO [on lines similar to that specific	ed for CYPs as			
list	red above]				
Unit 4:	Introduction to methods for studying DM	Hours: 5			
Unit 4.	Introduction to methods for studying DM	110015. 5			
• Di	scussion of in vitro and in vivo tools, along with their advantages	and limitations			
{re	combinant enzymes, subcellular fractions, hepatocytes, liver slices, pe	erfused liver and			
wh	ole animal studies}				
Unit 5:	Discussion of types of DM studies	Hours: 6			
Metabolic	stability, cross species comparisons, metabolite profiling and identificat	tion, reaction			
phenotypin	g, CYP inhibition and CYP induction studies.				
1 11					
Unit 6:	Introduction to in silico drug metabolite predictions and associated algorithms.	Hours: 3			
	Books:	•			
	1. Rick NG. Drugs From Discovery to Approval, second edition, John	n Wiley &			
	1. Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.	n Wiley &			
	1. Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.	n Wiley &			
	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations</li> </ol>	n Wiley &			
	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Baueld D. Marg. Elizabeth B. Andrews. Pharmaceuricilance accession</li> </ol>	n Wiley & Second Edition arch 26, 2002.			
	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma 3. Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wilay &amp; Song Ltd 2002</li> </ol>	n Wiley & Second Edition urch 26, 2002. nd edition, John			
	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shavne C. Gad. Drug Safety Evaluatio. A John Wiley &amp; Sons L</li> </ol>	n Wiley & Second Edition arch 26, 2002. and edition, John			
	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000</li> </ol>	n Wiley & Second Edition urch 26, 2002. ond edition, John Inc. Publication,			
Referenc	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg, Guidebook For Drug Regulatory Submissions</li> </ol>	n Wiley & Second Edition urch 26, 2002. Ind edition, John Inc. Publication,			
<b>Referenc</b> e	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> </ol>	n Wiley & Second Edition arch 26, 2002. and edition, John Inc. Publication, first edition, A			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> </ol>	n Wiley & Second Edition arch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> </ol>	n Wiley & Second Edition arch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement,</li> </ol>	n Wiley & Second Edition urch 26, 2002. Ind edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma</li> <li>Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement, John Wiley &amp; Sons Inc, January 1997.</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition,			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma 3. Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement, John Wiley &amp; Sons Inc, January 1997.</li> <li>Strom BI, Limmel SE. Textbook of Pharmacoepidemiology. C</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition, Chichester, West			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma 3. Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement, John Wiley &amp; Sons Inc, January 1997.</li> <li>Strom BI, Limmel SE. Textbook of Pharmacoepidemiology. C Sussex, England: John Wiley &amp; Sons Ltd; 2006.</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition, Chichester, West			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma 3. Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement, John Wiley &amp; Sons Inc, January 1997.</li> <li>Strom BI, Limmel SE. Textbook of Pharmacoepidemiology. C Sussex, England: John Wiley &amp; Sons Ltd; 2006.</li> <li>Rascati, Karen L. Essentials Of Pharmacoeconomics. Ph Lippincott Williams &amp; Wilking, 2009</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition, Chichester, West iladelphia, Pa.:			
Referenc e material:	<ol> <li>Rick NG. Drugs From Discovery to Approval, second edition, John Sons, Inc 2004.</li> <li>Allen Cato, Lynda Sutton, Clinical Drug Trials and Tribulations Revised, second edition, Marcel Dekker Inc; 2nd Revised edition Ma 3. Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance, seco Wiley &amp; Sons Ltd,2002.</li> <li>Shayne C. Gad, Drug Safety Evaluatio, A John Wiley &amp; Sons, I 2000.</li> <li>Sandy Weinberg. Guidebook For Drug Regulatory Submissions, John Wiley &amp; Sons, Inc. 2009.</li> <li>Duolao Wang and Ameet Bakhai Clinical Trials A Practical G Analysis, and Reporting, Remedica 2006.</li> <li>Giovanna di Ignazio, Di Giovanna and Haynes, Principals of Cl Wrightson Biomedical Pub., 2001</li> <li>R K Rondels, S A Varley, C F Webb, Clinical Datamanagement, John Wiley &amp; Sons Inc, January 1997.</li> <li>Strom BI, Limmel SE. Textbook of Pharmacoepidemiology. C Sussex, England: John Wiley &amp; Sons Ltd; 2006.</li> <li>Rascati, Karen L. Essentials Of Pharmacoeconomics. Ph Lippincott Williams &amp; Wilkins, 2009.</li> </ol>	n Wiley & Second Edition urch 26, 2002. and edition, John Inc. Publication, first edition, A duide to Design, inical Research, Second Edition, Chichester, West iladelphia, Pa.:			

2005.
12. Brenda Waning; Michael Montagne; William W McCloskey,
Pharmacoepidemiology: principles and practice, New York : McGraw-Hill, 2001
13. Various Guidelines like:
• ICH (International Conference on Harmonisation), GCP for registration of
• pharmaceuticals for human use. ICH Harmonised Tripartite
• Guideline for Good Clinical Practice, E6, 1996.
• ICMR Guideline – Ethical Guidelines for Biomedical Research on Human
Subjects.
• Indian GCP – Central Drugs Standard Control Organization. Good Clinical
Practices
• Guidelines for Clinical Trials on Pharmaceutical Products in India. New
Delhi: Ministry of Health; 2001.
Pharmacovigilance Programme of India (PvPI)

Course: Experimental Techniques in Pharmaceutical Sciences (CBCS, 2016)							
Course Code: MPH_C_299_L		: L	First Year M. Pharm			Semester: I	
Type of course: Practical		e:	Co	ntact Hours: 6 l	Hours/week	Total Contact 48	Hours:
Course asse Methods:	ssment	t	Con	tinuous mode o	f assessment	Semester assessm	-end Ient
Assessment	Tool*:	:	Theory Sessional Exam	Attendance	Total Internal Assessment	End sem Examina	ester ation
Max. Mark	s:		15	5	20	80	
Pre-requisit	tes:		Have practica concepts in vi	l knowledge in p tro and in vivo s	preparation of novel pha tudies.	rmaceutical prod	ucts,
Course Objectives:			The course air pharmaceutica and cosmetic	ms to impart a hi al product develo preparations.	gher level of practical u opment, statistical mode	ıp to date knowle els, bioavailabilit	dge in y studies
COURSE OUTCOMES PO Mapped PSO Mapped				PSO Mapped			
CO1	Desig	n nove	ovel drug delivery systems and evaluate them. 1, 3, 4, 6, 7			1, 2, 3	
CO2Apply the preformulation and excipient knowledge for proper design of safe, efficacious, stable and quality formulations.1, 2 7, 8			1, 2, 3, 4, 6, 7, 8, 10, 11	1, 2, 3			
CO3	Invest treatm	tigate v nent.	arious aspects	of dissolution an	d its mathematical	1, 2, 3, 4, 6, 7, 8, 11	1, 2, 3
CO4	Analy techni	vze the iques a	e the formulation parameters, apply optimization1, 2, 3, 4, 5,1, 2gues and devise suitable formulation composition.6, 7, 8, 9, 10,11			1, 2, 3	
				TOPIC	S		
<ol> <li>Study of dissolution profile of IR and ER products. Mathematical treatment of data for release Kinetics and f1 and f2 analysis.</li> <li>Simple Optimization design (formulation study/pH-stability study)</li> <li>Design and evaluation of Orally Disintegrating Drug Delivery System</li> <li>Preparation and evaluation of microspheres for inhalation system</li> <li>Preparation and evaluation of transdermal/mucoadhesive/gastroretentive system</li> <li>Constructing phase diagram for one system of oil, surfactant- cosurf, water</li> <li>Design of one vesicular system - niosomes/liposomes systems</li> <li>8. 8. Design of lipid particulate system (nanosystems with wax can be tried)</li> </ol>			ease				
material:			Survice 000KS Sp				

	Course: Rational Drug Design (CBCS)				
Cou MPI	ırse Code: H_E_221_T	First	First Year M. Pharm		
Type of Theor	of course: y	Contact Hours:	Contact Hours: 4 Hours/week (4L + 1T)		
Cours Metho	e assessment ods:	Continuou	Continuous mode of assessment		-end ent
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End semester Examination	
Max.	Marks:	15 5			
Pre-requisites:		<ul> <li>Before undertaking the course, students should have knowledge of the following:</li> <li>1. Basics of Protein 3D structure, computer applications</li> <li>2. Basics of organic chemistry related to bond characteristics.</li> <li>After completion of course students will be able to know:</li> <li>Role of Computer Aided Drug Design (CADD) in rational drug discovery</li> </ul>			ge of the s. l drug
Course Objectives:		<ul> <li>Different G</li> <li>Various st</li> <li>Working v</li> <li>The <i>in-sili</i></li> </ul>	cADD techniques and their apprategies to design and develop with molecular softwares to design virtual screening protocols	new drug like me	olecules
Course Outcomes		es: Upon completion of the course the student shall be able to:		PO Mapped	PSO mappe d
C01	Recall and re the structure a their interacti	late the different structures of protein along with activity relationship of existing studied drugs and lons with the protein residues.		1, 2, 3, 4, 7, 8, 11	1, 2, 3
CO2Classify and explain the different techniques to calculate the potential and kinetic energies of the system using Quantum and Molecular Mechanics, energy minimization and molecular1, 2, 38, 9, 1			1, 2, 3, 4, 5, 8, 9, 11	1, 2, 3	

	conformational space search in the binding cavity of protein.			
CO3	Make use of the minimal energy conformation of protein and ligand to construct and develop a model based on desired techniques like molecular docking, 3D-QSAR, pharmacophore modelling, homology modelling, molecular dynamics, etc.	d 1, 2, 4, 5, 6, 1, 2, d 8, 9, 11 r		
CO4	Analyze the results obtained based on the characteristics of different interactions (docking), equations (QSAR), binding energy (dynamics) and interpret the molecular mechanism of how a drug act in a particular manner to be either inhibiting or stimulating the enzyme/receptor.			
	Topics covered:			
Unit I	Molecular Mechanics		Hou	rs: 5
• paramo	<ul> <li>Molecular Mechanics and the forcefield. General form of a generic force field, force field parameterization.</li> <li>Self-Study – Comparison between the different force fields in existence at present time.</li> </ul>			
Unit I	Energy minimization		Hou	rs: 6
• limitat	• Steepest descents, conjugate gradients, Newton Raphson method, advantages and limitations of each method			
Unit I	I: Conformational analysis		Hou	rs: 10
• geome	Systematic search, Monte Carlo simulations, Molecular dynar try, strengths and limitations of each method.	nics simul	ations	, distance
Unit I	V: Docking		Hou	rs: 10
• Monte succes	Docking by energy minimization, superimposition, molecul Carlo, genetic algorithms, build-up approach. Different types o sful application of docking. Self-Study – Successful applications of docking.	ar dynam f scoring f	ics, M unctio	Aetropolis n, e.gs of
Unit V	: de novo ligand design		Hou	rs: 10
•	Classes of de novo ligand design – active site analysis methods,	whole-mo	lecule	methods,
connec applica	tion methods, random connection and disconnection meth tion of de novo ligand design.	ods, e.gs	of s	successful

• Fra	gment based drug design				
• Sel	f-Study – Successful applications of de novo drug design.				
Unit VI:	Pharmacophore modelling	Hours: 9			
• Teo based appro pharmacop	• Techniques of developing a pharmacophore map covering both ligand based and receptor based approaches, incorporating additional geometric features into a 3D pharmacophore, use of a pharmacophore model in drug design.				
• Sel	f-study - Successful e.g. of pharmacophore maps in drug design.				
Unit VII:	Virtual Screening Hours:				
• Virtual Screening based on similarity, docking, pharmacophore maps and filters for drug- likeness and ADME.					
Unit VIII:	3D-QSAR	Hours: 6			
• Co 4th, 5th and	MFA and CoMSIA. Mention of other 3D-QSAR techniques and intra- d 6th dimension in QSAR.	oduction to the			
• Sel	• Self-Study – 3D-QSAR methods other than CoMFA and CoMSIA.				
	Books:				
	1. Molecular Modelling – Principles and Applications, Leach Hall.	A. R., Prentice			
Referenc e	2. Practical Application of Computer-Aided Drug Design, Ed. Charifson P., Marcel Dekker Inc.				
material:	3. 3D QSAR in Drug Design: Theory, Methods and Applicatio H., Ledien ESCOM.	ns, Ed. Kubinyi			
	4. Molecular Modeling and Simulation -An Interdisciplinary Gu Springer.	uide, Schlick T.,			

	Course: Advanced Biochemistry (CBCS)				
Cou MPI	urse Code: H_E_222_T	First Year M. Pharm		Semester: II	
Type o Theor	of course: y	Contact Hours:	Total Contact H	Hours: 60	
Cours Metho	e assessment ods:	Continuous mode of assessment		Semester assessm	-end ent
Assess	sment Tool*:	Theory Sessional Exam	Theory Sessional Attendance Exam		
Max.	Marks:	15	5	80	
Pre-re	equisites:	Before undertaking the course, students should have knowledge of th following:1.Basics of chemical processes associated with living cells.2.Basics of biochemical pathways with enzymes.			
Cours	<ul> <li>After completion of course students will be able to know:</li> <li>Emphasizing on genetic organization of mammalian genome at hetero &amp; autocatalytic functions of DNA.</li> <li>Understand the catalytic role of enzymes, importance of enzyme inhibitors in design of new drugs, therapeutic and diagnostic applications of enzymes.</li> <li>Understand the metabolism of nutrient molecules in physiologic and pathological conditions.</li> <li>Understand the genetic organization of the mammalian genome</li> </ul>				me and enzyme stic iological enome eins.
Course Outcomes		: Upon completion of the course the student shall be able to:		PO Mapped	PSO mappe d
CO1	Recall the protein subfamilies along with defining the terminologies like metabolism, nucleic acid, enzymes, cofactors, biomolecules, etc.1, 2, 3, 4, 7, 8, 111, 2			1, 2, 3	
CO2	Classify and acids, purification	nomenclature of lipio ation, characterizatio	omenclature of lipids, carbohydrates and nucleic1ion, characterization and synthesis of proteins.8		

	Ap	ply the knowledge gained in understanding the effects of	1, 2, 3, 4	, 5,	1, 2, 3
	dru	gs on lipid metabolism, protein function, nucleic acid	8, 9, 11		
CO3	bio	synthesis, carbohydrates linkages to improve the			
	pha	rmacokinetic properties of certain drugs			
	Î	· · ·			
		<b>Topics covered:</b>			
Unit I	•	Proteins		Hou	rs: 15
•	Str	ucture - primary, secondary, tertiary, quaternary; motifs,	structural	and f	functional
	domains, protein families and macromolecular assemblies.				
•	Me lig	chanisms for regulating protein function: Protein-protein intrands: $C_{2}^{2}$ and GTP as modulators, cyclic phosphorylatio	eractions,	interac	orviation
	pro	teolytic cleavage.	n and dep	nospii	or yration,
•	Pu	rification and characterization of proteins: electrophoresis	s, ultracen	trifug	ation and
	liq	uid chromatography, use of biological assays, use of r	adioisotop	es; M	S, X-ray
	cry	stallography, NMR and homology modelling to determin	e structur	es; ar	nino acid
•	Pro	tein biosynthesis: translation machinery in prokaryotic	and euka	rvotic	systems:
	con	nparison of similarities and differences, drug affecting protei	n biosynth	esis a	nd protein
	fur	ction.			
Unit I	Unit II:DNA and nucleic acidsHours: 15				rs: 15
•	• DNA, RNA structure, nomenclature, double helix, conformations, higher order packing				
	and	architecture of DNA, transcription and replication of	DNA –	mecha	inisms in
	pro	karyotic and eukaryotic systems, DNA repair mechanisms,	drug affection	cting r	lucleotide
Unit I	Unit III: Carbohydrates Hours: 8				
	-				
•	Mo	no, di and polysaccharides and their nomenclature, stereoch	emistry, ty	pes of	linkages;
	COI pro	ijugates of carbonydrates with other molecules – gi teoglycans lipopolysaccharides and their biological roles	ycoprotein	is, gi	ycolipids,
Unit I	Unit IV: Lipids Hours: 7				rs: 7
		<b>K</b>			
•	• Classification, nomenclature, stereochemistry, storage lipids, membrane lipids, lipids as				lipids as
	me	tabolism.	ius, arug	arrec	ing npid
Unit V	Unit V: Self-study topics Hours: 15				rs: 15
•	Se	f-study of protein superfamilies, N and C terminal sequence	ing, DNA	struct	ures other
	tha	n B-DNA, DNA sequencing, DNA pyrosequencing, cerebros	ides, sphir	ngolipi	ds.
		Books:			
Refer	enc	• Principles of Biochemistry, Lehninger, Nelson D.I	L., C.B.S I	Publisl	ners, New
e		Delhi. Biochemistry Stryer I W H Erzamon & Co. No.	w Vork		
mater	ial:	<ul> <li>Molecular Cell Biology, Lodish H. Darnen J. Sc.</li> </ul>	vientific A	merica	n Books.
		N.Y.			
		Biochemistry- The chemical reactions of living cel Elsevier Academic Press.	ls, Vol 1 &	&2, Mo	etzler DE,

• Biochemistry, Berg JM, Tymoczko JL and Stryer L, WH Freeman and
Company and Sumanas Inc.
• Biomacromolecules- Introduction to structure, function and informatics,
Stan Tsai C, Wiley-Liss.
• Protein: Structure and Molecular properties, Thomas E Creighton, W. H.
Freeman.
• Physical Biochemistry- Principles and applications, Sheehan D, Wiley-
Blackwell.

Course: Green Chemistry (CBCS)						
Course Code: MPH_E_223_T		First	Semester: II			
Type o Theor	of course: y	Contact Hours: 4 Hours/week (4L + 1T)		Total Contact H	Iours: 60	
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Semester assessme	-end ent	
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End seme Examina	ester tion	
Max. I	Marks:	15	5	80		
Pre-requisites:		<ul> <li>Before undertaking the course, students should have knowledge of the following:</li> <li>1. Basics of organic chemistry reactions, like rearrangement reactions.</li> <li>2. Catalysts and use of catalysts in the reaction, nature and role of solvent used in synthesis.</li> </ul>				
Course Objectives:		<ul> <li>After completion of course students will be able to know:</li> <li>To introduce the learner with principles of green chemistry.</li> <li>To study the source, disposal and prevention of chemical waste.</li> <li>To learn basic level environmental management systems.</li> <li>To learn and select various kinds of catalysis with respect to industrial case studies.</li> </ul>				
Course Outcomes		Upon completion of the course the student shall be able to:		PO Mapped	PSO mappe d	
CO1	Know the terr various guide	ms involved in green lines of the environ	n chemistry and know mental management system.	1, 2, 3, 4, 8, 9, 10, 11	1, 2, 3	
CO2	Understand th and illustrate use of the mid	Inderstand the concept and techniques of waste management nd illustrate the twelve principles of green chemistry. Make se of the microwave concept in the synthetic reactions.			1, 2, 3	
CO3	Outline type of reaction solve	of catalysis and their ent.	r uses, safe solvents, water as	1, 2, 3, 4, 5, 7, 8, 10, 11	1, 2, 3	

CO4	Learn greener process designing and future prospects to be 1, 2, 3,			1, 2, 3
001	app	lied in their research areas. 7, 8, 10,	11	
		Topics covered:		
Unit I	:	Introduction to the concepts of Green Chemistry		
•	His	tory, need, goals, limitations, obstacles and opportunities.	Hour	rs: 5
•	Intr	aduction to the principles of Green Chemistry- Prevention of		
	Hour	rs: 15		
•	Mic son	rowave assisted organic synthesis; photochemical transformations; ication; solid phase transformations; aqueous phase transformations; ymatic transformations; etc.	Hour	rs: 8
•	Self	-Study - transformations using ionic liquids, PEG, polymer ported reagents.	Hour	rs: 4
Unit I	I:	Applications		
•	App reag exa	plication of green synthetic reactions, green starting materials, green gents, green solvents and reaction conditions, green catalysis and mples of green synthesis, green analytical methods.	Hour	rs: 13
•	Self	F-Study – Examples of Green synthesis	Hour	rs: 3
Unit I	II:	Future trends in green chemistry		
•	dation reduction reagents and catalysts; biomimetics and tifunctional reagents; combinatorial green chemistry; solventless ctions; non-covalent derivatization; biomass conversion; emission trol: biocatalysis	Hour	rs: 12	
		Books:		
Refere e materi	enc ial:	<ol> <li>Green Chemistry: Theory and Practice, Anastas P T and War University Press.</li> <li>Green Chemistry: Introductory Text, Lancaster M, RCS Lond</li> <li>Introduction to Green Chemistry, Ryan M. A., Tinnesand Chemical Society (Washington).</li> <li>Handbook of Green Chemistry and Technology, Clarke J and Blackwell Publishing.</li> <li>Green Chemistry – Greener alternative to synthetic organic Ahluwalia V K, Narosa Publications, New Delhi.</li> <li>Organic Synthesis – Special Techniques, Ahluwalia V K and</li> </ol>	ner J ( lon l M., . d Macc transfc nd Ag	C, Oxford American quarrie D, ormations, garwal R,

Course: Drug Regulatory Affairs (CBCS)						
Course Code: MPH_E_224_T		First	Semester: II			
Type Theor	of course: y	Contact Hours:	4 Hours/week (3L + 1T)	Total Co	ntact H	Iours: 60
Cours Metho	e assessment ods:	Continuou	s mode of assessment	Sen as	nester- sessm	-end ent
Assess	sment Tool*:	Theory Sessional Exam	Attendance	En Ex	d seme aminat	ester tion
Max.	Marks:	15	5		80	
Pre-re	equisites:	Have foundational management and c	knowledge in pharmaceutica communication skills.	al science,	pharn	naceutical
Cours	e Objectives:	The course aims to impart a higher level of theoretical up to date knowledge in international regulatory affairs and clinical trial studies related to pharmaceutical product development.				lies
Cou	irse Outcomes	be able to: <b>P</b>		PO Maj	pped	PSO mappe d
CO1	Understand the development guidelines for	ne concepts of innov process and the Reg r filing and approval	ator and generic drugs, drug ulatory guidance and process.	1,2,4,6,7	,9,11	1, 2
CO2	Develop and submit the dossiers in CTD/ eCTD formats and 1,7 the post approval regulatory requirements for actives and drug products				,8,10	1,2
CO3	D3 Understand the requirements in the clinical trials settings and pharmacovigilance activities			1,2,3,4,5 8,9,10,11	,6,7, I	1,2,3
CO4	CO4 To correlate the theoretical knowledge with professional and practical need of pharmaceutical industry.			1,2,3,4,5 8,10,11	,6,7,	3
		]	<b>Fopics covered:</b>			
Unit 1	: Need for	Regulations			Hour	rs: 1
Unit 2	: Indian R	legulations			Hour	rs: 15

1.	Introduction to Indian Regulations					
2.	Drugs & Cosmetic Act & Rules - Overview and recent amendments					
•	Schedule DI and DII (Registration and Import)					
•	Schedule M					
•	Schedule Y					
•	Central Drug Laboratories					
3.	ICMR guidelines for ethical considerations in biomedical research on hum	an subjects				
4.	BA - BE studies	5				
5.	New drug application					
6.	Insurance, Compensation and Indemnification of trial subjects Expert Refe	erral				
	• IBSC, RCGM					
	• ICMR					
	• NDAC					
	• CBBTDEC					
7.	WHO GMP Certification, FSC and CoPP procedure					
8.	Procedures for obtaining Test license (Form 29 and Form 11); Export NO	С				
9.	Loan license / Contract manufacturing					
Unit 3:	US Regulations	Hours: 6				
	Luca destina de UC Desenlacione					
•	Introduction to US Regulations					
•	Introduction to Orange Guide and 21 CEP					
•	Invoctional new drug (IND) filing					
•	IIVestigational new drug (IND) filing amondmonts and annual reports					
•	Abbraviated New Drug Application (ANDA) filing					
•	New Drug Application (NDA) filing					
_						
•	Post approval changes					
• Unit 4:	Post approval changes	Hours: 6				
• Unit 4:	Post approval changes European Regulations	Hours: 6				
• <b>Unit 4:</b> 1.	Post approval changes European Regulations Introduction to European Regulations	Hours: 6				
• Unit 4: 1. 2.	European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing	Hours: 6				
• Unit 4: 1. 2. 3.	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing	Hours: 6				
• Unit 4: 1. 2. 3. 4.	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures	Hours: 6				
• Unit 4: 1. 2. 3. 4. •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure	Hours: 6				
• Unit 4: 1. 2. 3. 4. •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)	Hours: 6				
• Unit 4: 1. 2. 3. 4. •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)	Hours: 6				
• Unit 4: 1. 2. 3. 4. • •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)	Hours: 6				
• Unit 4: 1. 2. 3. 4. • • • 5.	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (CP)         Handling variations         CW in UTE in	Hours: 6				
• Unit 4: 1. 2. 3. 4. • • • • 5. 6.	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU	Hours: 6				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure         21- CFR Part 11	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • 5. 6. Unit 5:	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure         21- CFR Part 11         Audits and Inspections. EDA 483's – Lessons learnt	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5: • • • • • • • • • • • • • • • • • • •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure         21- CFR Part 11         Audits and Inspections, FDA 483's – Lessons learnt         Overview of registration process in other geographice	Hours: 6 Hours: 10				
• Unit 4: 1. 2. 3. 4. • • • 5. 6. Unit 5: • • • • • • • • • • • • • • • • • • •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure         21- CFR Part 11         Audits and Inspections, FDA 483's – Lessons learnt         Overview of registration process in other geographies	Hours: 6 Hours: 10				
Unit 4: 1. 2. 3. 4. • • 5. 6. Unit 5: • • • • • • • • • • • • •	Post approval changes         European Regulations         Introduction to European Regulations         Active Substance Master File (ASMF) filing         CEP filing         Marketing Authorization and filing procedures         National Procedure         Mutual Recognition Procedure (MRP)         Decentralized Procedure (DCP)         Centralized Procedure (CP)         Handling variations         Clinical Trial Regulations in EU         Other applicable Regulations and Guidelines         Overview of ICH guidelines         CTD format of dossier         eCTD filing procedure         21- CFR Part 11         Audits and Inspections, FDA 483's – Lessons learnt         Overview of registration process in other geographies         Biological license application (BLA)	Hours: 6 Hours: 10				

Regulations governing Stem Cell therapeutics								
• Inti	Introduction to Pharmacovigilance and Drug Safety							
Orphan Medicinal Products								
Unit 6:	Intellectual Property Rights (IPR)	Hours: 4						
<ul> <li>Overview of patents from regulatory perspective</li> <li>PCT application &amp; general rules</li> <li>WTO / GATT system</li> <li>TRIPS Agreement</li> <li>Compulsory licensing</li> <li>Patent search, drafting and filing procedure</li> <li>Patent infringement analysis</li> <li>Trademark/ copyright filing procedures</li> </ul>								
Referenc e material:	<ul> <li>Books:</li> <li>1. Good Drug Regulatory Practices: A Regulatory Affairs Quality Drug Development Series, Vol 1, Helene I. Dumitriu <ul> <li>2.http://www.amazon.com/Good-Drug-Regulatory-</li> <li>PracticesDevelopment/dp/1574910515</li> <li>3. Guide to Drug Regulatory Affairs / Buch, Brigitte Friese.</li> <li>4. Drugs and Cosmetics Act, 1940 and Rules, 1945.</li> </ul> </li> <li>Useful links: <ul> <li>5. http://www.cdsco.nic.in/</li> <li>6. http://clinicaltrials.gov/</li> <li>7. http://dbtbiosafety.nic.in/</li> <li>8. http://www.emea.europa.eu/</li> <li>9. http://www.ich.org/</li> </ul> </li> </ul>	Manual (Good						

Course: Cosmeticology (CBCS Revised 2016)								
Course Code: MPHE_225 T		First Year M. Pharm			Semester: II			
Type cours Theo	of se: ory	C	ontact Hours: 4 Hours/	week (4L)	Total Contact Hours: 60			
Course Method	assess ls:	ment	Continuous moo	de of assessmer	nt	Semest assess	er-end ment	
Assessm	nent T	'ool*:	Theory Sessional Exam	Attendar	nce	End ser Examin	nester nation	
Max. N	larks:		15	5		80	)	
Pre- requisit	tes:	Have role c	basic knowledge of form of excipients.	ulation technolo	ogy and ur	nderstanding of	functional	
Course Objecti	ves:	The c	ourse will enable learners	s to take up cosr	netic scier	nce as career of	ption.	
<b>Course Outcomes</b> Upon completion of the course, the students will be able to				PO Mapped		PSO mapped		
CO1	Describe the role and functional performance of cosmetic excipients, therapeutics ingredients and perfumes in the formulation of cosmetics for skin, hair, nails and oral care.			ormance of gredients and etics for skin,	1,2,3,4	,6,7,9,10,11	1, 2,3	
CO2	Unde for th	erstand ne use o	the quality evaluation and of colors in cosmetics	d regulations	1,2,3,4	,6,7,9,10,11	1,2,3	
CO3	Form hair o	ulate a care as	nd evaluate cosmetics for well as dental and oral ca	r skin care and re	1,2,3,4,	5,6,7,8,10,11	1,2,3	
CO4	Design and evaluate herbal cosmetics for skin care, 1,2,3,4,5,6,7,8 hair care and oral care				5,6,7,8,10,11	123		
CO5	Utilize novel approaches of formulation technologies in delivery of functional ingredients to skin, hair nails and oral cavity.				1,2,3,4	,6,7,9,10,11	123	
CO6	Unde requi produ micro EU a	erstand rement ucts rel obiolog nd US	the packaging and labelities and quality standards of ated to safety, toxicity and gical standards in accordance requirements	ng f cosmetic d nce with BIS,	1,2,3,4	,6,7,9,10,11	1,2,3	

	Topics covered:						
	General Anatomy and Physiology of skin hair nail and						
Unit I:	tooth:	Hours: 8					
•	Anatomy and physiology of skin, hair, nail and tooth-emphasis on	points with reference					
to cosmetics.							
• Problems associated with normal functioning of skin, aged skin, dry skin, sensitive skin,							
	acne, pigmentation disorders.	1 1 11 11 /					
•	Common hair problems - hair loss, manageability problems, split of disorders; hail problems;	ends, shine and luster					
•	tooth problems						
IInit II	Canaral raw materials in cosmetic formulations:	Hours 19					
	Overview of raw materials. Water natural & synthetic oils fate &	waxes inorganic solids					
•	emulsifiers thickeners hydrocolloids polymers surfactants antic	waxes, morganic sonus, oxidants humectants					
	polysiloxanes, preservatives	induites, induite cuintes,					
•	Colouring agents used in cosmetics. Quality evaluation of colors,	safety, toxicity and					
	regulatory aspects of colors w.r.t. cosmetic products						
•	Perfumes in cosmetics: raw materials in perfumery, developing a p	perfume					
•	composition, current trends including emulsified and solid perfum	ery, analytical and					
	separation techniques of perfumes, sensory analysis, safety and to	xicological evaluation					
	perfumes, manufacturing and packaging of perfumes, registation	ii and regulations for					
•	Therapeutic ingredients in various cosmetics like skin products, de	entifrices, hair care and					
	nail preparations, and performance evaluation of these activities.	,					
•	Details of general raw materials (oils, fats, waxes, surfactants, pres	servatives,					
	polysiloxanes), Historical purview of perfumes, Approved colours	as per Indian,					
<b>TT 1</b> /	European and US specifications						
Unit III:	Application of novel approaches in cosmetic formulations	Hours: 4					
•	Concepts of microemulsions, liposomes, niosomes, nanoparticles,	iontophoresis, to					
	enhance functional attributes & delivery of cosmeceuticals.						
Unit IV:	Herbal cosmetics	Hours: 2					
•	Current trends in use of herbal materials in cosmetics.						
•	Discussion on aleo vera, henna, tea tree oil, neem in various cosmo	etic products					
Unit V	Packaging and labelling of cosmetic products	Hours: 5					
•	Packaging materials, speciality packages for cosmetics, labelling r cosmetics	requirements for					
Unit VI:	Quality standards of cosmetic products	Hours: 18					
•	BIS guidelines for quality of finished products for cosmetics, qual	ity control, textural					
	analysis, performance and psychometric evaluation of various cos	metic products such as					
	creams, gels, powders, lipstick, nail lacquer, shampoo, sunscreen j	products, dentifrices.					
•	Microbiological quality of cosmetic products						
•	Safety and toxicity evaluation of cosmetic products	ota					
	BIS European and US specifications about quality standards of	015					
•	cosmetic products						

cosmetic products

Г

	1.	Harry's Cosmeticology Edited by J.B. Wilkinson and R. J. Moore, Longman				
		Scientific & Technical Publishers				
	2.	Cosmetics Science and Technology, Edited by M.S. Balsam, E. Sagarin, S.D.				
		Gerhon, S.J.Strianse and M.M.Rieger, Volumes 1,2 and 3.Wiley-Interscience,				
	Wiley India Pvt. Ltd.,2008					
	3.	Poucher's Perfumes, cosmetics & Soaps, 10th Ed, Editor- Hilda Butler,				
		Klewer Academic Publishers, Netherlands, 2000				
Reference	4.	Cosmetic Technology, Ed. By S.Nanda, A. Nanda and R. Khar, Birla				
material:		Publications Pvt. Ltd., New Delhi, 2007				
	5.	Handbook of Cosmetic Science and Technology, edited by M. Paye,				
		A.O.Barel, H. I. Maibach, Informa Healthcare USA, Inc. 2007.				
	6.	Encyclopedia of Pharmaceutical Technology, Vol. 6, Eds. James Swarbrick,				
		James C. Boylan, Marcel Dekker Inc., 1992				
	7.	BIS Guidelines for different cosmetic products				
	8.	Drugs & Cosmetics Act & Rules, 1940 (with latest amendments).				

Course: Polymers in Pharmacy (CBCS Revised 2016)								
Cour MPH	se Cod E 226	e: T	First Year M. Pharm S			Ser	Semester: II	
Type of course: Theory		se:	Contact Hours: 4 H	Iours/week (4I	L)	Total Contact Hours: 60		
Course assessment Methods:			Continuous mod	le of assessmen	nt	Semester-end assessment		
Assessn	nent To	ool*:	Theory Sessional Exam	Attendar	nce		End sen Examin	nester ation
Max. M	larks:		15	5			80	
Pre- requisit	es:	Have substa	a fundamental understand ances like rheology, and the	ling of polymer nermal behavior	s and phy r.	ysic	cal properties	of
Course Objecti	ves:	The c being	ourse aims and equipping able to justify the use of 1	the learners wi right polymer in	th the kn 1 the forr	iow nul	ledge of poly ation.	mers and
Upon c	omplet	ion of	<b>Course Outcomes</b> the course, the students w	vill be able to	PC	) M	apped	PSO mapped
CO1	Study synthe	Study the classification and preparation methods of synthetic polymers				1,2,3,4,6,7,9,10,11 1, 2,3		
CO2	Study rheolo	Study the characterization of polymers1,2,3rheologically and thermally.1,2,3				1,2,3,4,6,7,9,10,11 1,2		1,2,3
CO3	Know unders polym	Know about biocompatibility of polymers and understanding the properties of biocompatible polymers are.1,2,3,4,5,6,7,8,10,111,2					1,2,3	
CO4	Expla applic	in why ations	y polymers are used in dru	ig delivery	1,2,3,4	,6,7	7,8,9,10,11	123
			Торіс	s covered:			·	
Unit I:	Hist	orical	Background, Basic defini	tions, Applicati	ions		Hours: 1	
Unit II:		ssifica	tion of Polymers:				Hours: 7	
<ul> <li>Classification based on reaction to temperature and structure/arrangement/architecture - linear, branched, cross-linked.</li> <li>Polymerization mechanisms- Addition &amp; step-growth polymerization-Free radical, cationic, anionic and Ziegler Natta mechanisms</li> </ul>						ical,		
Unit III:	Сор	olym	erization				Hours: 5	
•	Theore	tical a	spects of copolymerizatio	n nolumora				
• Unit	Self stt	iay- C	ase studies of any two co	polymers			11	
IV:	Pro	pertie	s & Characterization of	polymers			Hours: 12	

• F	Factors a	ffecting and Overview, Molecular weight and determin	nation of molecular					
W	weight.							
• S	Solid sta	te characterization- glass transition temperature, Crysta	allinity.					
• S	Solubilit	y of polymers & Swelling proreties, Mechanical proper	rties					
• 0	Case stud	dy-any 3 polymers – characteristics & comparison						
Unit V:	Meth	ods of Preparation of Polymers	Hours: 11					
• B	Bulk pol	ymerization, Solution polymerization,						
• S	Suspensi	on polymerization, Emulsion polymerization.						
• A	• Additives in polymers, Fabrication of polymeric devices/systems- casting, extrusion,							
n	noulding	g etc						
• (	One exar	nple polymer for each method						
Unit VI:	Bioco	mpatibility of Polymers	Hours: 10					
• S	Safety &	Biocompatibility issues- Overview						
• R	Reaction	of polymer to tissues, effect of body/host systems to p	olymers					
• N	Mechani	sms of tissue reactions/injury,						
• E	Evaluatio	on of biocompatibility of polymers						
• P	Pharmac	opoeial & other tests for toxicity evaluation of polym	ers					
Unit	Bioco	mpatible Polymers	Hours: 10					
VII:								
• 0	General	features of biocompatible polymers, enzymatically deg	radable bonds in polymers					
• E	Design o	f biocompatible polymers & evaluation,						
• S	Some exa	amples-PLGA, cellulosics, acrylates, hydrogels.						
Unit VII:	Appli	cations of polymers in pharmacy.	Hours: 4					
• 0	Dverview	v of applications as thickeners, binders, coating agents,	, adhesives, as release					
n	nodifyin	g agents, including smart polymers, elastomers						
• 0	One exar	nple each of – adhesive polymer, coating agent, drug r	elease modifier, smart					
р	olymer							
	1	. Fundamental Principles of Polymeric Materials by I	Rosen SL, Wiley-					
		Interscience Publication, 2nd edn, 1993.						
	2	2. Martin's Physical Pharmacy and Pharmaceutical Sciences by Sinko PJ, Ed Lea						
		& Feiger, Lippincott Williams & Wilkins, 6 <sup>th</sup> edn, 2010.						
	3	3. Controlled Drug Delivery: Fundamentals and Applications, Robinson JR, Lee						
	1	VHL, Dekker, 2 <sup>aa</sup> edn, Vol 29, 1987.						
Referenc	4	Margal Dalvar, Val 45, 1000	Chasin M, Langer K,					
motorial	. 5	Controlled and Nevel Drug Delivery by Join NK. C	DC Dublishans and					
material	. 5	Distributors 2008	bs Publishers and					
	6	Distributors, 2008.	Prost SD CDC Dress					
	0	Inc. Vol 2, 1983	Druk SD, CKC Pless					
	7	Inc., Vol 2, 1983. 7 Delameria Dava Delivera Statem ha Kana CS, Marcel Delaw, V, 1149						
1		Polymeric Drug Delivery System by Kwon CS Ma	rcel Dekker, Vol 148					
	/	<ul> <li>Polymeric Drug Delivery System by Kwon GS, Ma 2005</li> </ul>	rcel Dekker, Vol 148,					
	8	<ul> <li>Polymeric Drug Delivery System by Kwon GS, Ma 2005.</li> <li>Aqueous polymeric coating for pharmaceutical doss</li> </ul>	rcel Dekker, Vol 148,					

Course: Drug Evaluation Techniques (CBCS)							
Course Code: MPH_E_227_T		First Year M. Pharm		Semester: II			
Type Theor	of course: 'y	Contact Hours:	4 Hours/week (3L + 1T)	Total Co	ntact I	Hours: 60	
Cours Metho	se assessment ods:	Continuou	s mode of assessment	Ser as	nester sessm	-end ent	
Assess	sment Tool*:	Theory Sessional Exam	Attendance	End semester Examination		ester tion	
Max.	Marks:	15	5		80		
Pre-re	equisites:			I			
Cours	e Objectives:						
Cou	irse Outcomes	Upon completion of the course the student shall be able to:		PO Maj	pped	PSO mappe d	
CO1	Recall with ex- vitro methods	xamples the termino s available for target	logies associated with in ed drug delivery systems	1, 2, 3, 8	, 11	1, 2, 3	
CO2	Explain and i available for of drug disco	llustrate the various targeted drug deliver very and estimation	evaluation techniques ry systems, basic principles of drug from complex media	1, 2, 3, 4 8, 11	, 6,	1, 2, 3	
CO3	CO3 Apply the knowledge gained to perform in vitro assays and screening methods for different drugs and novel drug delivery systems					1, 2, 3	
		]	Fopics covered:				
Unit 1: Hours: 19							
<ol> <li>Basic principles of drug discovery and biological screening         <ul> <li>Correlation between various animal models and human situations.</li> <li>Correlation between in vitro and in vivo screens.</li> <li>Care, handling, breeding techniques of lab animals.</li> <li>CPCSEA, OECD, ICH guidelines in brief</li> </ul> </li> <li>High throughput screening in drug discovery</li> </ol>							

3. Techniques for high throughput screening.

	• Cel	l based assays						
	Biochemical assays.							
	• Rac	Radio ligand binding assays						
4.	Detection methods							
	Fluorescence based assay techniques							
	Chemiluminescence based assay techniques							
5.	Self-stu	dy Use of alternative methods of screening:						
6.	Zebrafis	sh model						
7.	Drosop	nila Types of drugs for which these models can be used						
Un	it 2: Tar	get based drug discovery and in vitro screening techniques for	Hours: 26					
1.	Anti-pla	atelet activity- Turbidimetric, GP IIB – IIIA assays using platelet aggre	gometer					
CN	S:							
	• Alz	heimer's disease: in vivo which includes aluminum induced, scopolam	ine induced					
	mer	nory loss. In vitro includes acetylcholenesterase activity.						
	• Par	kinson's disease: in vivo includes Haloperidol, reserpine, rotenone, MI	TP induced					
	moo	lels.						
	• Ant	i-depressant and anti-convulsants						
2.	Anti-dia	abetic: Alloxan, STZ, genetically diabetic animals and various in vitro	methods					
	• Ant	i-tubercular: BACTEC						
	• Ant	icancer: Few in vitro cell lines, models for metastasis.						
	• Ant	i-HIV: Various targets involved						
_	• Ant	i-malarial						
3.	Immuno	pmodulatory: in vivo and in vitro methods.						
4.	Anti-inf	lammatory: Acute, subacute and chronic models.						
5.	Self-stu	dy-Antioxidant activity						
Un	it 3: Esti	imation of drugs	Hours: 5					
	• Esti	mation of drugs from complex media like biological fluids Eg. blood,	tissues, CSF					
	etc.							
	• Self	-study-US FDA guidelines for bio analysis methods including validati	on.					
Un	it 4:		Hours: 5					
	• -In	vitro skin irritation and eye irritation tests						
	-In	vitro tests for pyrogenicity						
	• Self	-study-Alternative methods for toxicity testing (in vitro)						
		Books:						
		1. H.G. Vogel, Drug discovery and evaluation- Pharmacological Assa	ays-Springer					
Re	ferenc	Verlog.						
e		2. R.A.Turner, Screening methods in pharmacology- Academic Press						
ma	terial:	3. D.R.Laurence and A.L.Bacharach- Evaluation of drug activities:						
		Pharmacometrics. Academic Press.						
		4. A. Schwartz, Methods in Pharmacology- Plenum Publishing Corpo	oration.					
		5. WebsiteAltox.org/ttrc/validation-va						

# Semester – III and IV

#### M. Pharm. Semester III and Semester IV: ALL BRANCHES OF STUDY Total Credits: Semester III – 24 (MPH\_C\_301\_D), Semester IV-24 (MPH\_C\_401\_D)

#### Research work related to the title of the thesis that has been registered with the University.

The learner should be allotted a Research Guide in Semester I. The Guiding Teacher (Research Supervisor) along with the learner may plan the Research area to be pursued during Semesters III and IV. The title of the thesis should be communicated to the University before the commencement of Sem. III. Title change request if any, at a later time, should have a valid reason and will be considered under the existing rules of the University for title change (minor or major). Any request for change in title should be communicated to the University by the learner through the Research Guide and the Principal of the College/Institute. The learner is expected to work a minimum of 40 hrs/week in Research to be entitled for 24 Credits each in Semester III and IV. The Guiding Teacher (Research Supervisor) will sign a statement to this effect at the conclusion of Semesters III and IV, which may be communicated to the Controller of Examinations at the conclusion of each semester. Before completing the course, the learner will be required to give a Colloquium on the research work carried out by him/her during Semesters III and IV. The Colloquium will follow an open structure and will be assessed besides others by the Head of the Department, the Guide and the Principal of the College. A Statement that the learner has delivered a Colloquium must be sent to the University and will be mandated before the conduct of the viva-voce examination by the University.

Learners should be encouraged to attend conferences, seminars where they may present their research work, and to publish the findings of their research.

There will be no ESE at the end of Semester III. A learner will be permitted to submit his/her synopsis no earlier than 20 months (after 20 months) from the beginning of the M. Pharm program as instructed by the Government/Regulatory Authority for the respective year, BUT will have to submit the final thesis by the end of 24 months from the beginning of the M. Pharm program as instructed by the Government/Regulatory Authority. The time between submission of synopsis and thesis should be at least one month.

#### Any late submission of synopsis or thesis will result in the learner requiring to keep terms for the next semester and any subsequent semester/s till the learner finishes his/her degree.

At the end of Semester IV the learner will submit a thesis to the university. This will jointly be evaluated by the guiding teacher and an external examiner appointed by the university from academia or from the pharmaceutical industry. The evaluation will be for a total of 100 marks (value of 48 credits), of which 50 marks will be given by the guiding teacher and 50 marks by the external examiner. The parameters on which the marks will be given are: a. Literature Survey (10 marks) b. Presentation (8 marks) c. Methodology (7 marks) d. Results and Discussion (10 marks) and e. Vivavoce (15 marks). This makes a total of 50 marks each to be given by the guiding teacher and by the external examiner separately. These marks will be allotted to the course designated as MPH\_C\_301\_D + MPH\_C\_401\_D for a total value of 48 credits.

The submission of synopsis and the holding of the viva voce examination shall be done independent of the fact whether the student has successfully cleared semester I and Semester II. However, the result of the viva voce of M. Pharm. Examination will be declared only if the student has successfully cleared Semester I and Semester II examinations

Total Credits for M. Pharm:

Semester I -24 + Semester II -24 + Semester III - 24 + Semester IV - 24 = 96 credits